<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006041.pub2" GROUP_ID="COLOCA" ID="825005021509501761" MERGED_FROM="" MODIFIED="2013-02-27 13:09:16 +0000" MODIFIED_BY="Rasmus Moustgaard" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;/p&gt;" NOTES_MODIFIED="2013-01-25 13:34:31 +0100" NOTES_MODIFIED_BY="Henning Keinke Andersen" REVIEW_NO="088" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2013-02-27 13:09:16 +0000" MODIFIED_BY="Rasmus Moustgaard">
<TITLE>Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer</TITLE>
<CONTACT>
<PERSON ID="20056" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Wim</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Ceelen</LAST_NAME>
<SUFFIX/>
<POSITION>Surgeon</POSITION>
<EMAIL_1>wim.ceelen@ugent.be</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of GI Surgery</DEPARTMENT>
<ORGANISATION>Ghent University Hospital</ORGANISATION>
<ADDRESS_1>De Pintelaan 185</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ghent</CITY>
<ZIP>B-9000</ZIP>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>32-9-3326251</PHONE_1>
<PHONE_2>32-9-3323891</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-23 12:09:41 +0100" MODIFIED_BY="Henning Keinke Andersen">
<PERSON ID="49527087774604919281120723081709" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>De Caluwé</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Laura.deCaluwe@UGent.be</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of GI Surgery</DEPARTMENT>
<ORGANISATION>Ghent University Hospital</ORGANISATION>
<ADDRESS_1>De Pintelaan 185</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ghent</CITY>
<ZIP>B-9000</ZIP>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="86E06EEB82E26AA2008F53C83C29C06C" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Yves</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Van Nieuwenhove</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>yvniuewe@heel.vub.ac.be</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of GI Surgery</DEPARTMENT>
<ORGANISATION>Ghent University Hospital</ORGANISATION>
<ADDRESS_1>De Pintelaan 185</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ghent</CITY>
<ZIP>B-9000</ZIP>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>+32 2 476 3357</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="20056" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Wim</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Ceelen</LAST_NAME>
<SUFFIX/>
<POSITION>Surgeon</POSITION>
<EMAIL_1>wim.ceelen@ugent.be</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of GI Surgery</DEPARTMENT>
<ORGANISATION>Ghent University Hospital</ORGANISATION>
<ADDRESS_1>De Pintelaan 185</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ghent</CITY>
<ZIP>B-9000</ZIP>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>32-9-3326251</PHONE_1>
<PHONE_2>32-9-3323891</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-02-27 13:09:16 +0000" MODIFIED_BY="Rasmus Moustgaard">
<UP_TO_DATE>
<DATE DAY="16" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="4" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-25 12:54:40 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-01-25 12:53:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Review update with one new trial included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-01-25 12:54:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Review update with one new trial included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="26" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-25 13:34:31 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-01-25 12:55:09 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-07-27 12:09:37 +0200" MODIFIED_BY="[Empty name]">Radiotherapy alone versus radiotherapy combined with chemotherapy before operation of rectal cancer</TITLE>
<SUMMARY_BODY MODIFIED="2013-01-25 12:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with cancer of the rectum, the end part of the large bowel immediately above the anus, are treated with surgery. When the tumour is deemed to present a high risk of recurrence after surgery, a course of radiotherapy (RT) is administered before the operation. It has been proven in clinical studies that this 'preoperative' radiotherapy improves the outcome in rectal cancer patients. Recently, several studies have investigated the combination of radiotherapy with chemotherapy (CRT) before surgery. In theory, adding chemotherapy enhances the antitumour activity of radiotherapy. This meta-analysis has summarized the results of five studies that compared preoperative RT alone with preoperative CRT in rectal cancer patients. All of these studies were randomized, which means that the decision to administer either RT or CRT was determined by chance (ballot draw). The results of the meta-analysis may be summarized as follows. Compared to RT alone, preoperative CRT leads to increased side effects during treatment. Also, postoperative complications are somewhat increased, although the risk of dying from postoperative complications is similar. Preoperative CRT is more effective in causing tumour shrinkage (downstaging), and in preventing local recurrence of the disease. However, addition of chemotherapy did not result in more sphincter preserving surgeries, and did not affect the overall survival in rectal cancer patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-25 12:55:02 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-05-27 12:54:37 +0200" MODIFIED_BY="[Empty name]">
<P>Preoperative radiotherapy (RT) decreases local recurrence rate and improves survival in stage II and III rectal cancer patients. The combination of chemotherapy with RT has a sound radiobiological rationale, and phase II trials of combined chemoradiation (CRT) have shown promising activity in rectal cancer.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-05-27 12:47:12 +0200" MODIFIED_BY="[Empty name]">
<P>To compare preoperative RT with preoperative CRT in patients with resectable stage II and III rectal cancer. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-25 12:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Register of Controlled Trials, Web of Science, Embase.com, and Pubmed from 1975 until June 2012. A manual search was performed of Ann Surg, Arch Surg, Cancer, J Clin Oncol, Int J Radiat Oncol Biol Phys and the proceedings of ASTRO, ECCO and ASCO from 1990 until June 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-05-27 12:57:06 +0200" MODIFIED_BY="[Empty name]">
<P>Relevant studies randomized resectable stage II or III rectal cancer patients to at least one arm of preoperative RT alone or at least one arm of preoperative CRT.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-05-27 12:57:59 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome parameters included overall survival (OS) at 5 years and local recurrence (LR) rate at 5 years. Secondary outcome parameters included disease free survival (DFS) at 5 years, metastasis rate, pathological complete response rate, clinical response rate, sphincter preservation rate, acute toxicity, postoperative mortality and morbidity, and anastomotic leak rate. Outcome parameters were summarized using the Odds Ratio (OR) and associated 95% confidence interval (CI) using the fixed effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-01-25 12:55:02 +0100" MODIFIED_BY="[Empty name]">
<P>Five trials were identified and included in the meta-analysis. From one of the included trials only preliminary data are reported. The addition of chemotherapy to preoperative RT significantly increased grade III and IV acute toxicity (OR 1.68-10, P = 0.002) and marginally affected postoperative overall morbidity (OR 0.67-1.00, P = 0.05) while no differences were observed in postoperative mortality or anastomotic leak rate. Compared to preoperative RT alone, preoperative CRT significantly increased the rate of complete pathological response (OR 2.12-5.84, P &lt; 0.00001) although this did not translate into a higher sphincter preservation rate (OR 0.92-1.30, P = 0.32). The incidence of local recurrence at five years was significantly lower in the CRT group compared to RT alone (OR 0.39-0.72, P &lt; 0.001). No statistically significant differences were observed in DFS (OR 0.92-1.34, P = 0.27) or OS (OR 0.79-1.14, P = 0.58) at five years.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-05-27 12:53:18 +0200" MODIFIED_BY="[Empty name]">
<P>Compared to preoperative RT alone, preoperative CRT enhances pathological response and improves local control in resectable stage II and III rectal cancer, but does not benefit disease free or overall survival. The effects of preoperative CRT on functional outcome and quality of life are incompletely understood and should be addressed in future trials. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-25 13:34:31 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-01-25 12:55:46 +0100" MODIFIED_BY="[Empty name]">
<P>The incidence of fatal cases of colorectal cancer in Europe exceeds 200000 per year. Due to the specific anatomy and biology of rectal cancer, surgery alone historically has been associated with local recurrence in up to one in four patients. Locally recurrent disease is usually incurable, causes important morbidity and suffering and gives rise to systemic metastases. In the last few decades, improvements in surgical technique have dramatically lowered the incidence of locally recurrent disease. Careful pathological studies have clearly demonstrated that the major cause of local recurrence is the persistence of tumour foci within the mesorectum (<LINK REF="REF-Quirke-1986" TYPE="REFERENCE">Quirke 1986</LINK>; <LINK REF="REF-Quirke-2003" TYPE="REFERENCE">Quirke 2003</LINK>). Intact removal of the entire mesorectum (total mesorectal excision or TME) in cancers of the mid or lower third of the rectum was pioneered by Heald and has resulted in local recurrence rates lower than 5-10% (<LINK REF="REF-Heald-1982" TYPE="REFERENCE">Heald 1982</LINK>; <LINK REF="REF-Heald-1998" TYPE="REFERENCE">Heald 1998</LINK>; <LINK REF="REF-Enker-1999" TYPE="REFERENCE">Enker 1999</LINK>). The importance of complete removal of the surrounding mesorectum necessitates precise preoperative evaluation of the circumferential resection margin using imaging. Recently, magnetic resonance imaging (MRI) using a phased array coil has emerged as the imaging modality of choice in the preoperative evaluation of locally advanced rectal cancer (<LINK REF="REF-Beets_x002d_Tan-2003" TYPE="REFERENCE">Beets-Tan 2003</LINK>; <LINK REF="REF-Beets_x002d_Tan-2005" TYPE="REFERENCE">Beets-Tan 2005</LINK>; <LINK REF="REF-Brown-2004" TYPE="REFERENCE">Brown 2004</LINK>; <LINK REF="REF-Daniels-2005" TYPE="REFERENCE">Daniels 2005</LINK>; <LINK REF="REF-Brown-2006" TYPE="REFERENCE">Brown 2006</LINK>).<BR/>Parallel to improvements in surgical technique, adjuvant therapy regimens have been tested in clinical trials in an effort to reduce local recurrence rates. Neoadjuvant radiotherapy (RT) has been shown to significantly decrease local recurrence rate and improve survival provided a biologically equivalent dose (BED) of at least 30 Gy is administered (<LINK REF="REF-Gray-2001" TYPE="REFERENCE">Gray 2001</LINK>). The advantages of preoperative over postoperative RT include enhanced effectiveness in well oxygenated tissue, downstaging of advanced tumors and better treatment compliance (<LINK REF="REF-Glimelius-2002" TYPE="REFERENCE">Glimelius 2002</LINK>). The theoretical superiority of the preoperative approach over postoperative adjuvant therapy has been confirmed in the recent German rectal cancer trial (<LINK REF="REF-Sauer-2004" TYPE="REFERENCE">Sauer 2004</LINK>). The effect of preoperative RT on local recurrence rate is consistent even when optimal surgical technique (TME) is implemented. This was demonstrated by the results of the Dutch rectal cancer trial which randomized rectal cancer patients to undergo either RT followed by TME or TME alone in the setting of a national surgical training programme (<LINK REF="REF-Kapiteijn-2001" TYPE="REFERENCE">Kapiteijn 2001</LINK>, <LINK REF="REF-Peeters-2007" TYPE="REFERENCE">Peeters 2007</LINK>). Compared to TME alone, 5x5 Gray (Gy) of RT followed by TME resulted in a significantly lower local recurrence rate, although no improvement in overall survival (OS) was noted.<BR/>Although preoperative RT results in a complete pathological response in a minority of patients, significant downsizing is rarely achieved using short schedule RT regimens. In order to improve tumour response, preoperative RT has been combined with chemotherapeutic regimens. There is a strong radiobiological rationale to combine RT with chemotherapy. Combined chemoradiation (CRT) for rectal cancer was introduced in the adjuvant setting and subsequently in irresectable disease, where significant downsizing and downstaging was observed in many patients resulting in achievement of a resectable status in some cases (<LINK REF="REF-Minsky-1993" TYPE="REFERENCE">Minsky 1993</LINK>; <LINK REF="REF-Minsky-1997" TYPE="REFERENCE">Minsky 1997</LINK>). The argument for preoperative CRT in resectable disease is based primarily on possible downsizing and downstaging of tumors close to the circumferential resection margin or the sphincter apparatus, thereby enhancing both R0 resection and the sphincter preservation rate. The paramount importance of performing the resection with a negative CRM was shown in several clinical studies (<LINK REF="REF-Nagtegaal-2002" TYPE="REFERENCE">Nagtegaal 2002</LINK>). Secondly, the addition of chemotherapy could eliminate microscopic systemic disease present at the time of surgery. Possible concerns of preoperative CRT include an increase of both local and systemic toxicity and over treatment of inaccurately staged patients (<LINK REF="REF-Ammann-2003" TYPE="REFERENCE">Ammann 2003</LINK>). Several phase I and II studies using preoperative CRT have shown a promising tumour response with acceptable toxicity (<LINK REF="REF-Rodel-2003" TYPE="REFERENCE">Rodel 2003</LINK>; <LINK REF="REF-Osti-2004" TYPE="REFERENCE">Osti 2004</LINK>). A limited number of prospective randomized trials comparing preoperative RT alone with preoperative CRT in resectable rectal cancer are published or ongoing.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare preoperative RT with preoperative CRT in patients with resectable stage II or III rectal cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-25 13:34:31 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-01-25 13:34:03 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-01-25 12:55:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCT's) which randomized patients before surgery with curative intent to one of at least two schedules of preoperative therapy including RT and CRT.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with clinical stage II or III resectable rectal cancer undergoing preoperative RT or CRT followed by surgery.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Preoperative RT or CRT using fractionated external radiotherapy followed by surgery with curative intent (resectable rectal cancer). The surgical procedure must consist of rectal amputation or sphincter preserving anterior resection using an open or laparoscopic approach; local excisions are excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-25 13:34:03 +0100" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>- local recurrence rate at 5 years<BR/>Secondary<BR/>- overall survival at 5 years<BR/>- disease free survival at 5 years<BR/>- systemic metastasis rate<BR/>- pathological complete response rate<BR/>- clinical response rate<BR/>- sphincter preservation rate<BR/>- postoperative mortality within 30 days<BR/>- postoperative morbidity<BR/>- anastomotic leak rate</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-25 13:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>See: Colorectal Cancer Group methods used in reviews.</P>
<P>We searched the following electronic databases<BR/>- Cochrane Central Register of Controlled Trials<BR/>- ISI Web of Science (Science Citation Index, Current Contents) from 1975 until June 2012<BR/>- Embase.com<BR/>- Pubmed</P>
<P>Electronic database searches were performed with MeSH terms and free text terms:</P>
<P>-MeSH: \Rectal Neoplasms"[MeSH] AND\<BR/>Radiotherapy"[MeSH] AND \Drug Therapy"[MeSH]<BR/>-Free text terms:<BR/>rectal, rectum, cancer, adenocarcinoma, neoplasm, radiotherapy, irradiation, chemotherapy, chemoradiation, radiochemotherapy, combined modality, multimodal, preoperative, neoadjuvant</P>
<P>Manual search/abstract search</P>
<P>- Journals from 1990: Ann Surg, Arch Surg, Cancer, J Clin Oncol, Int J Radiat Oncol Biol Phys<BR/>- Proceedings from ASTRO, ECCO and ASCO</P>
<P>No language constraints were applied.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-01-25 13:23:21 +0100" MODIFIED_BY="[Empty name]">
<P>All three reviewers obtained the full text of all relevant studies and these were assessed for methodological quality according to the Cochrane Collaboration's tool for assessing the risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Methodological details relevant for potential bias included sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting. Disagreement was resolved by consensus.<BR/>Data were extracted by one reviewer (KF) on custom designed forms and entered in a computer database for transfer and statistical analysis in the Review Manager software. The data extracted included first author, year of publication, source, method of preoperative therapy and surgery, method of randomization, number of patients included, randomized, and analysed, and outcome parameters as listed above. Data accuracy was verified by the senior author (WPC).<BR/>RT dose was converted to the biologically equivalent dose (BED) using the linear quadratic equivalent formula (<LINK REF="REF-Dale-2005" TYPE="REFERENCE">Dale 2005</LINK>): BED = nd(1+1/(&#945;/&#946;)-(&#947;/&#945;)(T-T<SUB>k</SUB>), with n = number of fractions, d = dose per fraction, &#945;/&#946; = the linear quadratic quotient (set at 10 Gy), &#947;/&#945;= repair rate (set at 0.6 Gy/d), and T<SUB>k</SUB> = the initial time delay in days (set at 7). Differences between categorical outcome parameters were quantified using the odds ratio (OR) and corresponding 95% confidence interval (95CI). Summary statistics were calculated using the Mantel-Haenszel methods. Heterogeneity analysis was performed using the Q test, with significance accepted when P&lt;0.1. When present, heterogeneity was addressed as recommended by the Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-25 13:32:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-25 13:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>The initial search was performed in June 2007. Of a total of 17925 studies resulting from the primary search, 324 papers were selected for full review. In all, 320 papers were discarded (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Four randomized trials were identified comparing preoperative RT with preoperative CRT in resectable stage II or III rectal cancer (<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>; <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>; <LINK REF="STD-Bujko-2006" TYPE="STUDY">Bujko 2006</LINK>; <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>). The search was repeated, using similar criteria, in June 2012. A total of 1041 abstracts was selected and scrutinized, resulting in addition of one randomized trial (<LINK REF="STD-Latkauskas-2011" TYPE="STUDY">Latkauskas 2011</LINK>) to the search results.</P>
<P>
<LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>: From November 1972 through April 1976, Boulis-Wassif et al. recruited 247 patients with histologically proven localized adenocarcinoma of the rectum and no clinical of surgical evidence of distant metastases. All patients in both groups received preoperative RT by two parallel opposing diamond and chimney fields. All patients received a total dose of 34.5 Gy in 15 fractions of 2.3 Gy each over a total treatment time of 18 days (BED = 35.8 Gy). In the preoperative CRT group, intravenous 5-FU injection (375 mg/m<SUP>2</SUP>) was administered during the first 4 days of irradiation. Surgery usually followed within 2 weeks after the last irradiation. Two patients died before surgery. Assessed outcomes included ease of surgery, type of operation, radical resectability rate, histopathological response, postoperative mortality, postoperative period of hospitalizations, local control of the disease, distant metastases, disease free survival, and median survival. Follow-up was available up to 7 years.</P>
<P>
<LINK REF="STD-Bujko-2006" TYPE="STUDY">Bujko 2006</LINK>: From April 1999 until February 2002, Bujko et al. included 316 patients with resectable T3-T4 rectal carcinoma without sphincter infiltration and with a lesion accessible to digital rectal examination. Patients were randomised to either preoperative 5 x 5 Gy short-term RT (BED = 37.5 Gy) with subsequent total mesorectal excision (TME) performed within 7 days or to CRT to a total dose of 50.4 Gy (1.8 Gy per fraction during 25 days; BED = 42.2 Gy) concomitantly with two courses of bolus 5-fluorouracil (325 mg/m<SUP>2</SUP>) and leucovorin during weeks 1 and 5 of RT. Chemoradiation was followed by TME after 4-6 weeks. Three patients did not undergo surgery. Assessed outcomes were acute postirradiation toxicity, sphincter preservation rate, postoperative mortality, pathology, overall survival, disease free survival, local recurrence rate, distant metastases, late toxicity and incidence of permanent stoma. Median follow up was 48 months.</P>
<P>
<LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>: Between April 1993 and November 2003, Gerard et al. recruited 762 patients with a histologically confirmed, previously untreated rectal adenocarcinoma accessible to digital rectal examination (T3 or resectable T4 tumour with no evidence of distant metastases). Patients were allocated to two treatment arms: preoperative RT vs. preoperative CRT, both followed by surgery. RT was delivered with photons from a linear accelerator in a three- or four-field box technique. The dose per fraction was 1.8 Gy and all fields were treated each day with five fractions per week. The total dose was 45 Gy in 25 fractions during 5 weeks (BED = 42.2 Gy). Concurrent chemotherapy (CT) consisted of bolus 5-fluorouracil (350 mg/m<SUP>2</SUP>) and leucovorin administered during week 1 and 5 of RT. Surgery was planned between 3 and 10 weeks after the end of the preoperative RT (+/- CT). TME was recommended. Assessed outcomes were surgical procedures and postoperative complications, pathology, overall survival, progression free survival, and local recurrence. Median follow-up was 81 months.</P>
<P>
<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>: Between April 1993 and March 2003, Bosset et al. recruited 1011 patients with a T3 or resectable T4 M0 adenocarcinoma of the rectum within 15 cm from the anal margin and without previous treatment for this disease (EORTC 22921 trial). Patients were allocated to four treatment arms: preoperative RT, preoperative CRT, preoperative RT plus postoperative CT and preoperative CRT plus postoperative CT. Radiotherapy consisted of 45 Gy delivered to the posterior pelvis in 25 fractions of 1.8 Gy over a period of 5 weeks (BED = 42.2 Gy). The target volume of RT was not a classical pelvic volume but was limited to the main field of tumour spread and to the perirectal nodes. Preoperative chemotherapy was delivered in two 5-day courses of 5-fluorouracil (350 mg/m<SUP>2</SUP>) with leucovorin during the first and fifth weeks of RT. Surgery was scheduled to take place 3 to 10 weeks after treatment. TME was recommended beginning in 1999. Assessed outcomes were toxicity of the preoperative treatment, surgical procedures performed, rate of postoperative complications, pathology, late side effects, overall survival, disease free survival, and local and distant recurrence rate. Median follow-up of 5.4 years.</P>
<P>
<LINK REF="STD-Latkauskas-2011" TYPE="STUDY">Latkauskas 2011</LINK>: Latkauskas et al. evaluated 145 patients with histologically proven rectal cancer between 2007 and 2010. Eighty-three patients were e legible and randomized to receive either short term radiotherapy (5x5 Gy, N=37) or CRT (50 Gy in 25 fractions with 5-fluorouracil, N=46). In both groups, surgery was performed after a 6 weeks waiting period. Sample size was based on downstaging rate as primary endpoint; other endpoints were not defined. The included paper reports on preliminary data (surgical and pathological outcome).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-01-25 12:57:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was adequately performed in four studies using communication with a central office; the study by Latkauskas et al. does not specify the randomization method used. Three studies based randomisation on the minimization method (<LINK REF="STD-Bujko-2006" TYPE="STUDY">Bujko 2006</LINK>; <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>; <LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>). In the fourth study, the randomisation method is not specified (<LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>). None of the studies were described as double blind or used blinded outcome assessment. Description of withdrawals and dropouts was given in four out of five studies. There were no imbalances between treatment arms in the number of patients that did not undergo the complete trial procedure. Three studies were performed on an intention-to-treat basis (<LINK REF="STD-Bujko-2006" TYPE="STUDY">Bujko 2006</LINK>; <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>; <LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>); no imbalances were identified between treatment arms.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-01-25 12:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>The main primary outcome parameter was the local recurrence rate at five years, which was reported in three studies (<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>; <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>; <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>). In the RT group, 122 of 740 patients (16.5%) developed a local recurrence while in the CRT group this event was observed in 71 out of 754 patients (9.4%). (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>, <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>) This difference was statistically significant (OR 0.53, 95%CI 0.39-0.72, P &lt; 0.001). No statistically significant heterogeneity among studies was present (P = 0.12). Survival data at 5 years were available in three studies (<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>; <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>; <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>). In the CRT group, 644 of 1007 patients (63.9%) were alive at 5 years while in the RT group 647 of 993 patients (65.2%) survived 5 years. (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>) This difference did not reach statistical significance (OR 0.95, 95%CI 0.79-1.14, P = 0.58). No heterogeneity was present (P = 0.15).<BR/>The results of the analysis of the secondary outcome parameters were as follows. Disease free survival at 5 years, available in the studies of <LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK> and <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>, was 507/881 (57.5%) in the CRT group and 479/872 (54.9%) in the RT group. This difference was not statistically significant (OR 1.11, 95%CI 0.92-1.34, P = 0.27). (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>) Significant heterogeneity did not occur (P = 0.64). Grade III or IV treatment related toxicity developed in 151 of 1015 patients (14.9%) treated with CRT while in patients treated with RT alone, this occurred in 52 of 1017 patients (5.1%). (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) This difference was statistically significant (OR 4.1, 95%CI 1.68-10, P = 0.002). There was, however, significant heterogeneity (P = 0.005) which remained when the data were reanalysed using the random effects assumption. Among patients who underwent surgery, sphincter preservation was possible in 583 of 1157 patients (50.4%) in the CRT group and in 553 of 1145 patients (48.3%) in the RT group; this difference failed to reach statistical significance (OR 1.09, 95%CI 0.92-1.30, P = 0.32). (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) No heterogeneity was observed (P = 0.48). Postoperative 30 day mortality was observed in 31 of 1122 (2.8%) patients in th CRT group and in 21 of 1117 (1.9%) patients in the RT group. This difference did not reach statistical significance (OR 1.48, 95%CI 0.84-2.6, P = 0.17); no heterogeneity was detected (P = 0.6).<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> Postoperative morbidity was marginally higher in the CRT group (OR 0.67-1.00, P = 0.05) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) while no differences in anastomotic leak rate were detected (OR 0.62-1.84, P = 0.81). (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) Pathological complete response (i.e., ypT0N0) of the resected specimen was observed in 135 of 1142 patients (11.8%) in the CRT group and in 40 of 1142 patients (3.5%) in the RT group. (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) This difference was statistically significant (OR 3.52, 95%CI 2.12-5.84, P &lt; 0.00001) while significant heterogeneity for this parameter was not observed (P = 0.25).</P>
<P>Because of the limited number of included studies, no sensitivity analysis was performed.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-01-25 12:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Preoperative RT has been shown to reduce local recurrence rates and marginally improve survival over surgery alone provided a BED &gt; 30 Gy is delivered to the target region (<LINK REF="REF-Gray-2001" TYPE="REFERENCE">Gray 2001</LINK>). The current review addresses the question whether the addition of chemotherapy to preoperative RT further improves pathological and clinical outcome parameters. Five randomized trials were identified comparing preoperative CRT with preoperative RT alone in resectable, locally advanced rectal cancer. Although there was considerable variation in radiotherapy dose and fractionation, all five studies have used a BED &gt; 30 Gy. In three trials (<LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>; <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>; <LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>), RT regimens were identical in both groups. The study by Latkauskas et al. compared two different regimens, but with a similar interval to surgery (<LINK REF="STD-Latkauskas-2011" TYPE="STUDY">Latkauskas 2011</LINK>). In the Polish study (<LINK REF="REF-Bujko-2005" TYPE="REFERENCE">Bujko 2005</LINK>, <LINK REF="STD-Bujko-2006" TYPE="STUDY">Bujko 2006</LINK>), RT dose and fractionation as well as time interval until surgery were different in both groups (5x5 Gy followed by immediate surgery versus 50.4 Gy with chemotherapy followed by surgery after a waiting period of 4-6 weeks). In this study, therefore, it remains unclear whether the observed differences in tumour response between both arms are attributable to the addition of chemotherapy or to a different RT schedule and a different waiting period until surgery. Since, moreover, actuarial local recurrence data at five years are not available in this study, it was left out from the meta-analysis of local recurrence at five years. This analysis demonstrates a significant reduction in local recurrence rate with the addition of chemotherapy (OR 0.39-0.72, P &lt; 0.001). Importantly, the cumulative incidence rates of local recurrence in the RT group of the studies of <LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK> and <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK> (17%) and in both groups of the study of <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK> (15%) seem high compared to the 5.5% local recurrence rate at five years achieved by the Dutch rectal cancer trial using 5x5 Gy preoperative RT followed by surgery (<LINK REF="REF-van-den-Brink-2004" TYPE="REFERENCE">van den Brink 2004</LINK>). Differences in stage distribution and variation in surgical technique might explain this observation. Indeed, during the Dutch rectal cancer trial a formal surgical training and quality control program was implemented in order to guarantee optimal surgery (TME). The study of <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK> predated the introduction of TME surgery (inclusion period 1972-1976), whereas in the studies of <LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK> and <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>, TME surgery was 'recommended' without any formal surgical training or quality control.<BR/>Although in the study of <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK> a marginally significant five year survival benefit was associated with CRT, the combined analysis failed to demonstrate a significant difference in either overall or disease free survival at five years (OR 0.79-1.14, P = 0.58 and OR 0.92-1.34, P = 0.27, respectively). One of the hypotheses formulated to explain the observed lack of survival benefit found in many pre- or postoperative adjuvant therapy trials in rectal cancer is the existence of early, subclinical systemic disease present at diagnosis. This hypothesis is supported by the finding that the rate of distant metastatic disease in all four trials is consistently around 30%, without any difference between CRT and RT groups, indicating a future role of more effective systemic therapy to eradicate micrometastatic disease from the onset of therapy. Others have argued that the follow up time of the included trials is too short to observe a survival benefit, or that the incidence of local recurrence is too low to influence survival (<LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>).<BR/>Grade III and IV acute treatment related toxicity was more pronounced in the CRT group in the three studies reporting this parameter (<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>; <LINK REF="STD-Bujko-2006" TYPE="STUDY">Bujko 2006</LINK>; <LINK REF="STD-Gerard-2006" TYPE="STUDY">Gerard 2006</LINK>), with an overall OR of 1.68-10 and a P value of 0.002. However, chemotherapy related toxicity was generally acceptable as evidenced by the high compliance rates in the studies mentioned (82%, 78.1%, and 69% respectively). In resected patients, no differences were observed in 30 day mortality or anastomotic leak rate, but a marginally significant difference in overall postoperative morbidity was found. The results concerning anastomotic leakage should be interpreted with caution, since the exceedingly low leakage rate in the study of Bosset compared to currently accepted and published leakage rates following anterior resection suggests underreporting of this specific complication.<BR/>Postoperative quality of life (QoL) is an important, though often underreported aspect of cancer trials. From the Swedish and Dutch rectal cancer trials, it is known that preoperative 5x5 Gy followed by surgery significantly worsens functional outcome in terms of bowel, sexual, and bladder function compared to surgery alone (<LINK REF="REF-Holm-1996" TYPE="REFERENCE">Holm 1996</LINK>; <LINK REF="REF-Dahlberg-1998" TYPE="REFERENCE">Dahlberg 1998</LINK>; <LINK REF="REF-Peeters-2005" TYPE="REFERENCE">Peeters 2005</LINK>). A number of phase II trials have suggested that preoperative CRT followed by surgery does not adversely affect functional outcome (<LINK REF="REF-Feliu-2002" TYPE="REFERENCE">Feliu 2002</LINK>; <LINK REF="REF-Bosset-2000" TYPE="REFERENCE">Bosset 2000</LINK>). The scarce available data in the four included studies did not allow to perform a meta-analysis of QoL related parameters. However, preliminary functional outcome data of the EORTC 22921 study (published as abstract only) demonstrated a significantly worse anorectal function in CRT patients compared to RT alone (<LINK REF="REF-Mercier-2005" TYPE="REFERENCE">Mercier 2005</LINK>). Interestingly, in the final results paper of this study the incidence of 'late side effects' including fecal incontinence did not seem to differ between the four treatment arms (<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>).<BR/>The results of the meta-analysis confirm the enhanced cytotoxic efficacy of combined RT with 5-fluorouracil based chemotherapy. The incidence of a complete pathological response (pCR, ypT0N0) was 135 of 1142 patients (11.8%) in the CRT group and 40 of 1142 patients (3.5%) in the RT group; this difference was statistically highly significant (OR 3.52, 95%CI 2.12-5.84, P &lt; 0.00001) while no heterogeneity was observed between the four studies. The results of the EORTC study moreover confirmed the difference in radioresponsiveness of the tumour in the bowel wall compared to that of mesorectal lymph nodes, as evidenced by nodal involvement in up to 12% of ypT0 patients (<LINK REF="REF-Bosset-2004" TYPE="REFERENCE">Bosset 2004</LINK>). Although in two studies (<LINK REF="STD-Bosset-2006" TYPE="STUDY">Bosset 2006</LINK>; <LINK REF="STD-Boulis_x002d_Wassif-1984" TYPE="STUDY">Boulis-Wassif 1984</LINK>) a trend towards increased sphincter preservation was observed in the CRT group, the overall results failed to demonstrate an increase in sphincter preserving surgery following CRT notwithstanding the downsizing and downstaging effect often noted with the combined therapy. This finding may be related to reluctance of the colorectal surgeon to alter a preoperative assessment of the need to perform a rectal amputation, since reversal of this decision would possibly imply performing an anastomosis in previously macroscopically invaded tissue. Moreover, in at least two studies it was specifically advised not to change a preoperative decision to perform a rectal amputation even after a significant downsizing. Data from the German rectal cancer trial, however, suggested that a change in operative strategy (i.e., perform sphincter preserving surgery when a significant clinical response is observed) may be safely performed. Longer follow up will be needed to confirm the safety of this approach. Mature results (including recurrence and survival data) from the study by Latkauskas et al. are awaited. An ongoing study by the Berlin Cancer Society, randomises patients with histologically proven rectal cancer staged T2N+ or T3 to receive either SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days or CRT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later (<LINK REF="STD-Siegel-2009" TYPE="STUDY">Siegel 2009</LINK>). All patients receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU) and are followed up for 5 years. TME-quality is independently documented by the surgeon and the pathologist; the primary endpoint is local recurrence at five years.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-25 12:59:19 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-25 12:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>Compared to preoperative RT alone, preoperative CRT enhances tumour response and improves local recurrence rates. The addition of chemotherapy causes a moderate increase in acute toxicity and overall postoperative morbidity, although anastomotic leakage rate or 30 day mortality are not enhanced. At this moment, it is unclear from the available data whether the addition of chemotherapy to preoperative RT influences sphincter preservation. Patients should be informed about the possible functional and QoL related aspects of preoperative therapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. Since the improvement of local control obtained with CRT did not translate into a better overall or disease free survival and up to one third of all patients develop distant spread, priority should be given to trials addressing early subclinical systemic spread;<BR/>2. Trials are needed that specifically address the oncological safety of performing sphincter preserving surgery (including intersphincteric resection and colo-anal anastomosis) in patients deemed to require amputation before the start of CRT and in whom a significant clinical response is observed;<BR/>3. Preoperative therapy trials in rectal cancer should include formal evaluation of functional and QoL related aspects of therapy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-07-16 16:26:46 +0200" MODIFIED_BY="[Empty name]">
<P>Wim P Ceelen is a senior clinical researcher of the Fund for Scientific Research - Flanders (FWO).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-07-27 15:09:56 +0200" MODIFIED_BY="[Empty name]">
<P>General coordination and writing: Wim Ceelen, Yves Van Nieuwenhove</P>
<P>Literature search, data extraction, data verification: Laura De Caluwé, Wim Ceelen, Yves Van Niewenhove</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-25 13:28:48 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-25 13:14:43 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-01-25 13:14:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bosset-2006" MODIFIED="2013-01-25 13:03:58 +0100" MODIFIED_BY="[Empty name]" NAME="Bosset 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-25 13:03:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al.EORTC Radiotherapy Group Trial 22921</AU>
<TI>Chemotherapy with Preoperative Radiotherapy in Rectal Cancer</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>1114-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boulis_x002d_Wassif-1984" MODIFIED="2013-01-25 13:09:10 +0100" MODIFIED_BY="[Empty name]" NAME="Boulis-Wassif 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-01-25 13:09:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boulis-Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N</AU>
<TI>Final Results of a Randomized Trial on the Treatment of Rectal Cancer with Preoperative Radiotherapy Alone or in Combination With 5-Fluorouracil, Followed by radical surgery</TI>
<SO>Cancer</SO>
<YR>1984</YR>
<VL>53</VL>
<PG>1811-1818</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bujko-2006" NAME="Bujko 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M</AU>
<TI>Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer</TI>
<SO>British Journal of Surgery</SO>
<YR>2006</YR>
<VL>93</VL>
<PG>1215-1223</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerard-2006" MODIFIED="2013-01-25 13:13:55 +0100" MODIFIED_BY="[Empty name]" NAME="Gerard 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-25 13:13:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gérard J-P, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M-T, et al.</AU>
<TI>Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-T4 Rectal Cancers: Results of FFCD 9203</TI>
<SO>J Clin Oncol</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>4620-4625</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Latkauskas-2011" MODIFIED="2013-01-25 13:14:19 +0100" MODIFIED_BY="[Empty name]" NAME="Latkauskas 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-25 13:14:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Latkauskas T, Pauzas H, Gineikiene I, Janciauskiene R, Juozaityte E, Saladzinskas Z, et al.</AU>
<TI>Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery</TI>
<SO>Colorectal Dis</SO>
<YR>2011</YR>
<VL>14</VL>
<NO>3</NO>
<PG>294-298</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-01-25 13:14:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Siegel-2009" MODIFIED="2013-01-25 13:14:43 +0100" MODIFIED_BY="[Empty name]" NAME="Siegel 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-25 13:14:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, et al.</AU>
<TI>Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society</TI>
<SO>BMC Cancer</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-25 13:28:48 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-01-25 13:28:48 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ammann-2003" MODIFIED="2013-01-25 13:19:26 +0100" MODIFIED_BY="[Empty name]" NAME="Ammann 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ammann K, Kirchmayr W, Klaus A, Muhlmann G, Kafka R, Oberwalder M, et al.</AU>
<TI>Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum</TI>
<SO>Archives of Surgery</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>3</NO>
<PG>257-261</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beets_x002d_Tan-2003" NAME="Beets-Tan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Beets-Tan RGH, Beets GL</AU>
<TI>Rectal cancer: how accurate can imaging predict the T stage and the circumferential resection margin?</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>385-391</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beets_x002d_Tan-2005" NAME="Beets-Tan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Beets-Tan RGH, Lettinga T, Beets GL</AU>
<TI>Pre-operative imaging of rectal cancer and its impact on surgical performance and treatment outcome</TI>
<SO>Ejso</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>6</NO>
<PG>681-688</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosset-2000" MODIFIED="2013-01-25 13:19:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bosset 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bosset JF, Magnin V, Maingon P, Mantion G, Pelissier EP, Mercier M, et al.</AU>
<TI>Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>2</NO>
<PG>323-327</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosset-2004" MODIFIED="2013-01-25 13:20:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bosset 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L, Maingon P, et al.</AU>
<TI>Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance - Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group</TI>
<SO>European Journal of Cancer</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>2</NO>
<PG>219-224</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004" MODIFIED="2013-01-25 13:20:30 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2004" NOTES="&lt;p&gt;768TP&lt;/p&gt;" NOTES_MODIFIED="2013-01-25 13:20:30 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Brown G, Kirkham A, Williams GT, Bourne M, Radcliffe AG, Sayman J, et al.</AU>
<TI>High-resolution MRI of the anatomy important in total mesorectal excision of the rectum</TI>
<SO>American Journal of Roentgenology</SO>
<YR>2004</YR>
<VL>182</VL>
<NO>2</NO>
<PG>431-439</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0361-803X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2006" MODIFIED="2013-01-25 13:21:47 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2006" NOTES="&lt;p&gt;ISI Document Delivery No.: 099AX&lt;/p&gt;" NOTES_MODIFIED="2013-01-25 13:21:47 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Brown G, Daniels IR, Heald RJ, Quirke P, Blomqvist L, Sebag-Montefiore D, et al.</AU>
<TI>Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study</TI>
<SO>British Medical Journal</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7572</NO>
<PG>779-782</PG>
<MD>Article</MD>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0959-8146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bujko-2005" NAME="Bujko 2005" NOTES="&lt;p&gt;975GH&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bujko K, Nowacki MP, Kepka L, Oledzki J, Bebenek M, Kryj M; Polish Colorectal Study Group.</AU>
<TI>Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation</TI>
<SO>Colorectal Disease</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>4</NO>
<PG>410-416</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1462-8910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahlberg-1998" NAME="Dahlberg 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dahlberg M, Glimelius B, Graf W, Pahlman L</AU>
<TI>Preoperative irradiation affects functional results after surgery for rectal cancer - Results from a randomized study</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>5</NO>
<PG>543-549</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dale-2005" MODIFIED="2008-05-27 13:22:14 +0200" MODIFIED_BY="[Empty name]" NAME="Dale 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dale R, Carabe-Fernandez A</AU>
<TI>The radiobiology of conventional radiotherapy and its application to radionuclide therapy</TI>
<SO>CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS    </SO>
<YR>2005</YR>
<VL>20</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daniels-2005" NAME="Daniels 2005" TYPE="JOURNAL_ARTICLE">
<AU>Daniels IR</AU>
<TI>High spatial resolution MRI predicts turnout spread in patients with rectal cancer - Results from the MERCURY study</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>3</NO>
<PG>688-689</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enker-1999" MODIFIED="2013-01-25 13:22:26 +0100" MODIFIED_BY="[Empty name]" NAME="Enker 1999" TYPE="JOURNAL_ARTICLE">
<AU>Enker WE, Merchant N, Cohen AM, Lanouette NM, Swallow C, Guillem J, et al.</AU>
<TI>Safety and efficacy of low anterior resection for rectal cancer - 681 consecutive cases from a specialty service</TI>
<SO>Annals of Surgery</SO>
<YR>1999</YR>
<VL>230</VL>
<NO>4</NO>
<PG>544-552</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feliu-2002" MODIFIED="2013-01-25 13:22:41 +0100" MODIFIED_BY="[Empty name]" NAME="Feliu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Feliu J, Calvillo J, Escribano A, de Castro J, Sanchez ME, Mata A, et al.</AU>
<TI>Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>5</NO>
<PG>730-736</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glimelius-2002" MODIFIED="2008-07-30 10:00:13 +0200" MODIFIED_BY="[Empty name]" NAME="Glimelius 2002" TYPE="JOURNAL_ARTICLE">
<AU>Glimelius B</AU>
<TI>Radiotherapy in rectal cancer</TI>
<SO>Br Med Bull</SO>
<YR>2002</YR>
<VL>64</VL>
<PG>141-157</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2001" MODIFIED="2013-01-25 13:22:57 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gray R, Hills R, Stowe R, Clarke M, Peto R, Buyse M, et al.</AU>
<TI>Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<NO>9290</NO>
<PG>1291-1304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heald-1982" NAME="Heald 1982" NOTES="&lt;p&gt;Pm993&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Heald RJ, Husband EM, Ryall RDH</AU>
<TI>The Mesorectum in Rectal-Cancer Surgery - the Clue to Pelvic Recurrence</TI>
<SO>British Journal of Surgery</SO>
<YR>1982</YR>
<VL>69</VL>
<NO>10</NO>
<PG>613-616</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0007-1323"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heald-1998" NAME="Heald 1998" TYPE="JOURNAL_ARTICLE">
<AU>Heald RJ, Moran BJ, Ryall RDH, Sexton R, MacFarlane JK</AU>
<TI>Rectal cancer - The Basingstoke experience of total mesorectal excision, 1978-1997</TI>
<SO>Archives of Surgery</SO>
<YR>1998</YR>
<VL>133</VL>
<NO>8</NO>
<PG>894-898</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-01-25 13:25:47 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors).</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].</TI>
<SO>The Cochrane Collaboration. Available from www.cochrane-handbook.org.</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holm-1996" NAME="Holm 1996" TYPE="JOURNAL_ARTICLE">
<AU>Holm T, Singnomklao T, Rutqvist LE, Cedermark B</AU>
<TI>Adjuvant preoperative radiotherapy in patients with rectal carcinoma - Adverse effects during long term follow-up of two randomized trials</TI>
<SO>Cancer</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>5</NO>
<PG>968-976</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapiteijn-2001" MODIFIED="2013-01-25 13:26:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kapiteijn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al.</AU>
<TI>Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>9</NO>
<PG>638-646</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mercier-2005" MODIFIED="2013-01-25 13:26:34 +0100" MODIFIED_BY="[Empty name]" NAME="Mercier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mercier M, Pasquet P, Puyraveau M, Bosset J, Calais G, Mineur L, et al.</AU>
<TI>Evaluation of the sphincter function and quality of life in French patients with rectal cancer who entered the EORTC 22921 study.</TI>
<SO>Eur J Cancer</SO>
<YR>2005</YR>
<VL>Supplements 3, No.2</VL>
<PG>171</PG>
<CY>Paris, France</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minsky-1993" MODIFIED="2013-01-25 13:26:49 +0100" MODIFIED_BY="[Empty name]" NAME="Minsky 1993" TYPE="JOURNAL_ARTICLE">
<AU>Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Schwartz G, et al.</AU>
<TI>Preoperative Combined 5-Fu, Low-Dose Leucovorin, and Sequential Radiation-Therapy for Unresectable Rectal-Cancer</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>5</NO>
<PG>821-827</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minsky-1997" MODIFIED="2013-01-25 13:27:06 +0100" MODIFIED_BY="[Empty name]" NAME="Minsky 1997" TYPE="JOURNAL_ARTICLE">
<AU>Minsky BD, Cohen AM, Enker WE, Saltz L, Guillem JG, Paty PB, et al.</AU>
<TI>Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>1997</YR>
<VL>37</VL>
<NO>2</NO>
<PG>289-295</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagtegaal-2002" NAME="Nagtegaal 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nagtegaal ID, Marijnen CAA, Kranenbarg EK, van de Velde CJH, van Krieken J</AU>
<TI>Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma - Not one millimeter but two millimeters is the limit</TI>
<SO>American Journal of Surgical Pathology</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>3</NO>
<PG>350-357</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osti-2004" NAME="Osti 2004" TYPE="JOURNAL_ARTICLE">
<AU>Osti MF, Valeriani M, Masoni L, Tombolini V, Enrici RM</AU>
<TI>Neoadjuvant chemoradiation for locally advanced carcinoma of the rectum</TI>
<SO>Tumori</SO>
<YR>2004</YR>
<VL>90</VL>
<NO>3</NO>
<PG>303-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peeters-2005" MODIFIED="2013-01-25 13:27:32 +0100" MODIFIED_BY="[Empty name]" NAME="Peeters 2005" TYPE="JOURNAL_ARTICLE">
<AU>Peeters K, van de Velde CJH, Leer JWH, Martijn H, Junggeburt JMC, Kranenbarg EK, et al.</AU>
<TI>Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients - A dutch colorectal cancer group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>25</NO>
<PG>6199-6206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peeters-2007" MODIFIED="2013-01-25 13:27:59 +0100" MODIFIED_BY="[Empty name]" NAME="Peeters 2007" TYPE="JOURNAL_ARTICLE">
<AU>Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al., Dutch Colorectal Cancer Group</AU>
<TI>The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma</TI>
<SO>Ann Surg</SO>
<YR>2007</YR>
<VL>246</VL>
<PG>693-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quirke-1986" NAME="Quirke 1986" NOTES="&lt;p&gt;E6070&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Quirke P, Dixon MF, Durdey P, Williams NS</AU>
<TI>Local Recurrence of Rectal Adenocarcinoma Due to Inadequate Surgical Resection - Histopathological Study of Lateral Tumor Spread and Surgical Excision</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>2</VL>
<NO>8514</NO>
<PG>996-999</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0140-6736"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Quirke-2003" NAME="Quirke 2003" TYPE="JOURNAL_ARTICLE">
<AU>Quirke P</AU>
<TI>Training and quality assurance for rectal cancer: 20 years of data is enough</TI>
<SO>Lancet Oncology</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>11</NO>
<PG>695-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodel-2003" NAME="Rodel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R</AU>
<TI>Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>16</NO>
<PG>3098-3104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sauer-2004" MODIFIED="2013-01-25 13:28:30 +0100" MODIFIED_BY="[Empty name]" NAME="Sauer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al.</AU>
<TI>Preoperative versus postoperative chemoradiotherapy for rectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>17</NO>
<PG>1731-1740</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Brink-2004" MODIFIED="2013-01-25 13:28:48 +0100" MODIFIED_BY="[Empty name]" NAME="van den Brink 2004" NOTES="&lt;p&gt;ISI Document Delivery No.: 859PY&lt;/p&gt;" NOTES_MODIFIED="2013-01-25 13:28:48 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>van den Brink M, Stiggelbout AM, van den Hout WB, Kievit J, Kranenbarg EK, Marijnen CAM, et al.</AU>
<TI>Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>19</NO>
<PG>3958-3964</PG>
<MD>Article</MD>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0732-183X"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-25 13:02:15 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-01-25 13:02:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-01-25 12:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosset-2006">
<CHAR_METHODS>
<P>1.Randomization method: telephone to central office (assumed)<BR/>2. Abdominal imaging: CT<BR/>3. Chest imaging: CXR<BR/>4. 4 arm study: Arm 1 preop RT + S; Arm 2 preop XRT + concurrent 5FU LV + S;Arm 3 preop RT + S + post op 5FU LV ; Arm 4 preop RTCT+ S + postop 5FU LV<BR/>5. Total randomized 1011</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1. Rectal Cancer<BR/>2. Location: within 15 cm from anal verge<BR/>3. Resectability: locally resectable<BR/>4. T3 or resectable T4 (defined by clinical criteria or endoscopic ultrasound)<BR/>5. WHO PS 0-1<BR/>6. &lt;/=80yr</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-25 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>1.Surgery: AP/anterior resection or Hartman with TME<BR/>2. RT : 45 Gy in 25fr.<BR/>3. RT volume: 5cm above and below tumour and perirectal nodes below S2-3. If tumour above 10cm, include<BR/>only 3 cm above tumour. If tumour in low rectum, S2-3 to perineum. Posteriorly to include entire sacrum with 3cm beyond macroscopic extension<BR/>4. RT-S: within 3-10 weeks of completing neoadjuvant therapy<BR/>5. 3 or 4 field<BR/>6. Chemotherapy: 5FU 325mg/m2/d; Leucovorin 20mg/m2/day Dy1-5 &amp; 28-32 for arms 2 and 4, and<BR/>postoperative for arms 3 and 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Duration of FU: 5.4 yrs<BR/>2. Perioperative mortality: CRTS 2.4 % (12/506) RTS 1.2% (6/505)<BR/>3. Mets (liver) @ lap: Y<BR/>4. Curative resection: not stated<BR/>5. Overall resection: 94.5 %<BR/>6. Compliance to radiotherapy: CRTS 483/506 (95.5%) RTS 495/505 (98.0%)<BR/>7. OAS: Y<BR/>8. CSS?<BR/>9. Tox post RT: Y<BR/>10. Acute tox post S: Y<BR/>11. Late tox post S: Y<BR/>12. LR: Y<BR/>13. QOL: N<BR/>14. Proportion sfincter sparing: CRTS 267/506 (52.8%) RTS 255/505 (50.5%)<BR/>15. Proportion downstaging: Y</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-25 13:01:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boulis_x002d_Wassif-1984">
<CHAR_METHODS>
<P>1.Randomization method: not stated. conducted by cooperative group. Likely via central office<BR/>2. Abdominal imaging: Not stated<BR/>3. Chest imaging: Not stated<BR/>4. Study arm (Preop chemoradiotherapy arm) : 171randomized, 45 excluded.<BR/>5. Control arm (Preop radiotherapy arm): 168 randomized , 47 excluded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1. Rectal Cancer<BR/>2. Location: below within 15cm anal verge<BR/>3. Resectability: fit for surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-25 13:01:50 +0100" MODIFIED_BY="[Empty name]">
<P>1.Surgery: AP/anterior resection<BR/>2. RT : 3450 cGy in 15fr. (for both arms)<BR/>3. BED: 35.2Gy1<BR/>4. RT volume: ''chimney and diamond fields" paraaortic and pelvis.<BR/>5. RT-S: within 2 wk<BR/>6. 2 field<BR/>7. Cointervention: none<BR/>8. 2 arms, control (Radiotherapy followed by surgery), Study (Chemoradiotherapy followed by surgery)<BR/>9.Chemotherapy: 5FU 10mg/kg/d day 1-4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1.Duration of FU: mean 5.2yrs<BR/>2. Perioperative mortality: CRTS 19/126 RTS 11/121<BR/>3. Mets @ lap: CRTS 13/126 RTS 15/121<BR/>4. Curative resection: Not stated<BR/>5. Overall resection: CRTS 121, RTS 124<BR/>6. Compliance to radiotherapy: not given<BR/>7. OAS: Y<BR/>8. CSS: N<BR/>9. Tox post RT: not given<BR/>10: Acute tox post S: not given<BR/>No complication not given<BR/>11. Late tox post S: not given<BR/>12: LR: N<BR/>13. QoL:N</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bujko-2006">
<CHAR_METHODS>
<P>1.Randomization method: telephone to central office<BR/>2. Abdominal imaging: ultrasound or CT<BR/>3. Chest imaging: CXR<BR/>4. XRT + S arm : (short XRT)155 randomized, 0 excluded.<BR/>5. Arm B: (Long XRT+CT): 157 randomized , 0 excluded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1. Rectal Cancer<BR/>2. Location: inferior edge palpable of digital exam<BR/>3. Resectability: locally resectable<BR/>4. T3 or resectable T4<BR/>5. not involving sphincter</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Surgery: AP/anterior resection or Hartman with TME<BR/>2. RT : XRT +S arm: 2500cGy cGy in 5fr. ; Arm B: 50.4Gy in 28 fr with concomitant CT weeks 1 &amp; 5<BR/>3. BED: Arm A 38.7Gy10, Arm B 40.9Gy10<BR/>4. RT volume: Not stated<BR/>5. RT-S: XRT+S within 7 days; Arm B: within 4-6 weeks<BR/>6. 3 or 4 field<BR/>7. Arm B chemotherapy: 5FU 325mg/m2/d; Leucovorin 20mg/m2/day Dy1-5 &amp; 28-32</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1.Duration of FU: not stated<BR/>2. Perioperative mortality: XRT+S 0/155 Arm B 0/157<BR/>3. Mets @ lap: not stated<BR/>4. Curative resection: not stated<BR/>5. Overall resection: XRT+S 145/155 Arm B 147/157<BR/>6. Compliance to radiotherapy: XRT+S 152/155 Arm B 141/157<BR/>7. OAS: N<BR/>8. CSS: N<BR/>9. Tox post RT: no complications XRT+S 118/155 Arm B 24/157 Any complications XRT+S 37/155 Arm<BR/>B 133/157 Gd 3-4 XRT + S 5/155 Arm B 26/157 Gd 5 (Death) XRT +S 0/155 Arm B 2/157<BR/>10: Acute tox post S: Not stated<BR/>11. Late tox post S: not given<BR/>12: LR: N<BR/>13. QoL:N<BR/>14. Proportion sphincter sparing<BR/>15. Proportion downstaged (by T stage, N stage, Tumor size)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gerard-2006">
<CHAR_METHODS>
<P>1.Randomization method: not stated<BR/>2. Abdominal imaging: liver sonography - CT scan<BR/>3. Chest imaging: CXR<BR/>4. Study arm: CRT 375<BR/>5. Control arm: RT 367</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1. Rectal Cancer<BR/>2. Location: accessible by digital examination<BR/>3. Resectability: locally resectable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 arms: preop XRT vs preop CRT<BR/>1.Surgery: TME recommended<BR/>2. RT 45Gy in 25 fr for both arms<BR/>3. BED: 32.5Gy10<BR/>4. RT volume: NA<BR/>5. RT-S: NA<BR/>6. NA<BR/>7. Cointervention: postoperative CT (5FU FA) x 4 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1.Duration of FU: 81m<BR/>2. Perioperative mortality (60 days): 2% for both arms<BR/>3. Mets @ lap: not stated<BR/>4. Curative resection: not stated<BR/>5. Overall resection: not stated<BR/>6. Compliance to radiotherapy: not stated<BR/>7. OAS: Y<BR/>8. CSS: Y<BR/>9. Tox (gr 3-4) post RT: Preop RT arm: 10/367 CRT arm: 55/375 <BR/>10: Acute tox post S: not stated<BR/>11. Late tox post S: Y</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-25 13:02:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Latkauskas-2011">
<CHAR_METHODS MODIFIED="2012-07-16 11:52:52 +0200" MODIFIED_BY="[Empty name]">
<P>1. Randomization method: not stated</P>
<P>2. Abdominal imaging: abdominal US, EUS, CT scan and MRI pelvis</P>
<P>3. Chest imaging: CXR</P>
<P>4. Study arm: CRT 46<BR/>5. Control arm: RT 37</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-16 11:55:01 +0200" MODIFIED_BY="[Empty name]">
<P>1. Rectal cancer stage II and III</P>
<P>2. less than 15 cm from anal verge</P>
<P>3. &lt;80 years old, no other cancer during last 5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-25 13:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. CRT: 50 Gy in 25 fractions, 1.8-2 Gy/fraction over 5 weeks with 5-FU/LV during week 1 and 5</P>
<P>2. RT: 25 Gy in 5 fractions</P>
<P>3. Surgery: after 6 weeks in both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-16 12:01:38 +0200" MODIFIED_BY="[Empty name]">
<P>1. Duration of FU: not stated<BR/>2. Perioperative mortality: not stated<BR/>3. Mets @ lap: not stated<BR/>4. Curative resection: 91.3% (CRT), 86.5% (RT)<BR/>5. Overall resection: 37/37 (RT), 46/46 (CRT)<BR/>6. Compliance to radiotherapy: not stated<BR/>7. OAS: not stated<BR/>8. CSS: not stated<BR/>9. Tox (gr 3-4) post RT: not stated<BR/>10: Acute tox post S: not stated<BR/>11. Late tox post S: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-07-27 15:17:49 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-07-27 15:17:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siegel-2009">
<CHAR_STUDY_NAME MODIFIED="2012-07-27 15:12:56 +0200" MODIFIED_BY="[Empty name]">
<P>Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-07-27 15:13:05 +0200" MODIFIED_BY="[Empty name]">
<P>Prospective Randomized trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-27 15:14:29 +0200" MODIFIED_BY="[Empty name]">
<P>Primary rectal cancer within 12 cm from anal verge, cT3N+, cT3N0, or cT2N+</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-27 15:15:32 +0200" MODIFIED_BY="[Empty name]">
<P>Short course RT consists of single doses of 5.0 Gy in five fractions within one week up to a total dose of 25 Gy. For CRT, standard fractions of 1.8 Gy/d are given 5 times a week up to a total dose of 50.4 Gy; concomitant chemotherapy consists of continuous 5-FU-infusion 225 mg per square meter per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-27 15:15:58 +0200" MODIFIED_BY="[Empty name]">
<P>Local recurrence after five years follow up has been chosen as primary endpoint.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-07-27 15:16:39 +0200" MODIFIED_BY="[Empty name]">
<P>2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-07-27 15:17:49 +0200" MODIFIED_BY="[Empty name]">
<P>Peter M Schlag email: <A HREF="mailto:pmschlag@charite.de">pmschlag@charite.de</A>
</P>
<P>Department of Surgery and Surgical Oncology, Charité &#8211; Universitätsmedizin Berlin, Berlin, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-07-15 16:07:46 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-07-15 16:07:46 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bosset-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Boulis_x002d_Wassif-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bujko-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gerard-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-15 16:07:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latkauskas-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-01-25 13:02:16 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-01-25 13:02:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>excluded studies</TITLE>
<TABLE COLS="2" ROWS="9">
<TR>
<TH>
<P>Type</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<TR>
<TD>
<P>Non randomized trials</P>
</TD>
<TD>
<P>144</P>
</TD>
</TR>
<TR>
<TD>
<P>Adjuvant therapy trials</P>
</TD>
<TD>
<P>28</P>
</TD>
</TR>
<TR>
<TD>
<P>Trials not including at least one chemotherapy arm combined with radiotherapy</P>
</TD>
<TD>
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>Trials not including radiotherapy</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>Trials using local or no resection</P>
</TD>
<TD>
<P>18</P>
</TD>
</TR>
<TR>
<TD>
<P>Trials including other tumour types</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P>Trials not including stage II/III cancer</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>Total</P>
</TD>
<TD>
<P>320</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-07-15 16:03:39 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-07-15 16:03:39 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>radiotherapy vs radiochemotherapy</NAME>
<DICH_OUTCOME CHI2="3.7790057905034686" CI_END="1.2654459335473813" CI_START="0.875862497058965" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0527851800105863" ESTIMABLE="YES" EVENTS_1="363" EVENTS_2="346" I2="47.076027112053076" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.10224359456449701" LOG_CI_START="-0.057564069009776946" LOG_EFFECT_SIZE="0.02233976277736005" METHOD="MH" MODIFIED="2008-06-22 13:15:57 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1511470356482223" P_Q="1.0" P_Z="0.583710547402442" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1007" TOTAL_2="993" WEIGHT="100.00000000000001" Z="0.5479728504565003">
<NAME>Overall Survival at 5y</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.7548599330367605" CI_START="1.0060950317500217" EFFECT_SIZE="1.6648275862068966" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="50" LOG_CI_END="0.4400995226594477" LOG_CI_START="0.0026390043932634426" LOG_EFFECT_SIZE="0.22136926352635555" MODIFIED="2008-06-22 12:54:54 +0200" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.2569664738940462" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="126" TOTAL_2="121" VAR="0.06603176870553952" WEIGHT="10.615204303711502"/>
<DICH_DATA CI_END="1.3841103136665973" CI_START="0.7480706119832492" EFFECT_SIZE="1.0175520868225363" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="118" LOG_CI_END="0.14117070479376742" LOG_CI_START="-0.12605740621668493" LOG_EFFECT_SIZE="0.00755664928854124" MODIFIED="2008-06-22 12:54:41 +0200" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.15697111520802304" STUDY_ID="STD-Gerard-2006" TOTAL_1="375" TOTAL_2="367" VAR="0.024639931009650437" WEIGHT="36.376920900130955"/>
<DICH_DATA CI_END="1.2365235870119429" CI_START="0.7366426074965641" EFFECT_SIZE="0.9543982184431623" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="178" LOG_CI_END="0.09220240505755065" LOG_CI_START="-0.13274316510981535" LOG_EFFECT_SIZE="-0.020270380026132344" MODIFIED="2008-06-22 12:54:27 +0200" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.13213414141484142" STUDY_ID="STD-Bosset-2006" TOTAL_1="506" TOTAL_2="505" VAR="0.017459431327437307" WEIGHT="53.007874796157544"/>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.6582776953924135" CI_END="1.1726866723550997" CI_START="0.8851723259718955" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="1.0188374695724562" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.06918198940062792" LOG_CI_START="-0.052972172315466304" LOG_EFFECT_SIZE="0.008104908542580787" MODIFIED="2008-06-24 12:06:56 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8829707579045218" P_Q="1.0" P_Z="0.7947969926540057" Q="0.0" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.26008657614743325">
<NAME>HR_OS</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.2566530463631553" CI_START="0.8277971495615423" EFFECT_SIZE="1.0199283356036581" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.09921538838688936" LOG_CI_START="-0.08207607338322277" LOG_EFFECT_SIZE="0.008569657501833233" MODIFIED="2008-06-24 12:02:18 +0200" MODIFIED_BY="[Empty name]" ORDER="67" O_E="1.74" SE="0.10649150205097282" STUDY_ID="STD-Bosset-2006" TOTAL_1="0" TOTAL_2="0" VAR="88.18" WEIGHT="45.40062524970859"/>
<IPD_DATA CI_END="1.660655835102639" CI_START="0.8033626480514651" EFFECT_SIZE="1.155036306438102" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.22027963582095253" LOG_CI_START="-0.09508836444184081" LOG_EFFECT_SIZE="0.06259563568955581" MODIFIED="2008-06-24 12:02:53 +0200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="4.2" SE="0.18524872445114315" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="0" TOTAL_2="0" VAR="29.14" WEIGHT="15.003109772924791"/>
<IPD_DATA CI_END="1.445735905901589" CI_START="0.6779220379160105" EFFECT_SIZE="0.9899980967745114" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.16008896717379711" LOG_CI_START="-0.16882024779914584" LOG_EFFECT_SIZE="-0.004365640312674334" MODIFIED="2008-06-24 12:03:39 +0200" MODIFIED_BY="[Empty name]" ORDER="69" O_E="-0.2693" SE="0.19320290100197887" STUDY_ID="STD-Bujko-2006" TOTAL_1="0" TOTAL_2="0" VAR="26.79" WEIGHT="13.793181565430856"/>
<IPD_DATA CI_END="1.2662170179353922" CI_START="0.7278330032862289" EFFECT_SIZE="0.9599971536291393" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.10250814613519793" LOG_CI_START="-0.13796825539979204" LOG_EFFECT_SIZE="-0.01773005463229706" MODIFIED="2008-06-24 12:04:10 +0200" MODIFIED_BY="[Empty name]" ORDER="70" O_E="-2.046" SE="0.14125702863903886" STUDY_ID="STD-Gerard-2006" TOTAL_1="0" TOTAL_2="0" VAR="50.1164" WEIGHT="25.80308341193576"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="0.21880562436596965" CI_END="1.0863914172339106" CI_START="0.7446845190238546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8994547626281594" ESTIMABLE="YES" EVENTS_1="374" EVENTS_2="393" I2="0.0" I2_Q="100.0" ID="CMP-001.03" LOG_CI_END="0.03598632591408117" LOG_CI_START="-0.12802767445312332" LOG_EFFECT_SIZE="-0.046020674269521056" METHOD="MH" MODIFIED="2008-06-22 13:16:06 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6399514998217877" P_Q="0.0" P_Z="0.27137908827126855" Q="2.0749299473825112E-32" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="881" TOTAL_2="872" WEIGHT="100.0" Z="1.099892252009801">
<NAME>Disease free survival at 5 y</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.141621178096874" CI_START="0.6374418298529558" EFFECT_SIZE="0.8530633580015956" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="163" LOG_CI_END="0.057522016733515736" LOG_CI_START="-0.1955594408964101" LOG_EFFECT_SIZE="-0.06901871208144719" MODIFIED="2008-06-22 12:48:35 +0200" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.14866130098523817" STUDY_ID="STD-Gerard-2006" TOTAL_1="375" TOTAL_2="367" VAR="0.022100182410623576" WEIGHT="43.124200482867835"/>
<DICH_DATA CI_END="1.19768319666279" CI_START="0.7293517476392875" EFFECT_SIZE="0.9346295162278015" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="230" LOG_CI_END="0.07834195650382522" LOG_CI_START="-0.13706297207128382" LOG_EFFECT_SIZE="-0.029360507783729294" MODIFIED="2008-06-22 12:48:53 +0200" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.1265299213166121" STUDY_ID="STD-Bosset-2006" TOTAL_1="506" TOTAL_2="505" VAR="0.016009820988388043" WEIGHT="56.875799517132165"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8598216407868418" CI_END="2.6251791238260997" CI_START="0.8329756744735304" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4787529716902945" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.4191589419649033" LOG_CI_START="-0.07936768118165324" LOG_EFFECT_SIZE="0.16989563039162503" METHOD="MH" MODIFIED="2012-07-15 15:58:37 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6020045794212256" P_Q="1.0" P_Z="0.18158398224139835" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1168" TOTAL_2="1154" WEIGHT="99.99999999999999" Z="1.3358938168500651">
<NAME>Mortality 30 d</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="5.3953189948458" CI_START="0.7476397833950548" EFFECT_SIZE="2.008421052631579" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.7320171271664232" LOG_CI_START="-0.1263075970079662" LOG_EFFECT_SIZE="0.30285476507922854" ORDER="6" O_E="0.0" SE="0.5041841917559444" STUDY_ID="STD-Bosset-2006" TOTAL_1="487" TOTAL_2="483" VAR="0.2542016992165949" WEIGHT="33.7344370452378"/>
<DICH_DATA CI_END="5.215943178011927" CI_START="0.6674040099703916" EFFECT_SIZE="1.8657817109144543" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.7173328515869222" LOG_CI_START="-0.17561118829737543" LOG_EFFECT_SIZE="0.27086083164477337" ORDER="7" O_E="0.0" SE="0.524519749172321" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="124" TOTAL_2="121" VAR="0.2751209672717945" WEIGHT="31.169384522201927"/>
<DICH_DATA CI_END="5.572720774867552" CI_START="0.04486138999238514" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7460672829678747" LOG_CI_START="-1.3481272742958372" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8" O_E="0.0" SE="1.2301402493669504" STUDY_ID="STD-Bujko-2006" TOTAL_1="152" TOTAL_2="153" VAR="1.5132450331125828" WEIGHT="5.666862293528311"/>
<DICH_DATA CI_END="2.8887755609631203" CI_START="0.3481370801305808" EFFECT_SIZE="1.0028409090909092" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.46071380130365114" LOG_CI_START="-0.4582497174842679" LOG_EFFECT_SIZE="0.0012320419096915837" ORDER="9" O_E="0.0" SE="0.539803719878806" STUDY_ID="STD-Gerard-2006" TOTAL_1="359" TOTAL_2="360" VAR="0.29138805599499645" WEIGHT="29.429316139031954"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-15 15:58:37 +0200" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.0" STUDY_ID="STD-Latkauskas-2011" TOTAL_1="46" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.975837840191777" CI_END="1.0039715252437307" CI_START="0.6686625929891454" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8193401023730867" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="263" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.0017213954734540166" LOG_CI_START="-0.17479297186934736" LOG_EFFECT_SIZE="-0.08653578819794668" METHOD="MH" MODIFIED="2012-07-15 15:59:49 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3953657086566743" P_Q="1.0" P_Z="0.054638954846370776" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1044" TOTAL_2="1033" WEIGHT="100.0" Z="1.921736239321243">
<NAME>Postop morbidity</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.3188657402336337" CI_START="0.7250725348756317" EFFECT_SIZE="0.9778922872340425" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="112" LOG_CI_END="0.12020058687051381" LOG_CI_START="-0.1396185452627925" LOG_EFFECT_SIZE="-0.00970897919613936" ORDER="10" O_E="0.0" SE="0.1526190443405506" STUDY_ID="STD-Bosset-2006" TOTAL_1="487" TOTAL_2="483" VAR="0.023292572695422953" WEIGHT="46.154905420043974"/>
<DICH_DATA CI_END="1.280641068055895" CI_START="0.43793102215672597" EFFECT_SIZE="0.7488874761602035" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" LOG_CI_END="0.1074274248222695" LOG_CI_START="-0.3585942891666774" LOG_EFFECT_SIZE="-0.125583432172204" ORDER="11" O_E="0.0" SE="0.27374346164179597" STUDY_ID="STD-Bujko-2006" TOTAL_1="152" TOTAL_2="153" VAR="0.07493548279163342" WEIGHT="14.346561197665048"/>
<DICH_DATA CI_END="1.0109141448144514" CI_START="0.5071537041766356" EFFECT_SIZE="0.7160229417743574" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="97" LOG_CI_END="0.004714273279806427" LOG_CI_START="-0.2948603981434557" LOG_EFFECT_SIZE="-0.14507306243182463" ORDER="12" O_E="0.0" SE="0.1759716449125639" STUDY_ID="STD-Gerard-2006" TOTAL_1="359" TOTAL_2="360" VAR="0.030966019813233474" WEIGHT="34.71761938508191"/>
<DICH_DATA CI_END="1.3112156497928213" CI_START="0.20435881584466242" EFFECT_SIZE="0.5176470588235295" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.11767412404177849" LOG_CI_START="-0.689606622497989" LOG_EFFECT_SIZE="-0.28596624922810526" MODIFIED="2012-07-15 15:59:49 +0200" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.4742007066216032" STUDY_ID="STD-Latkauskas-2011" TOTAL_1="46" TOTAL_2="37" VAR="0.2248663101604278" WEIGHT="4.780913997209068"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.568900115144856" CI_END="10.004255765711756" CI_START="1.678967344786047" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="4.098392213968493" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="52" I2="81.07655500373146" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.0001847862389304" LOG_CI_START="0.22504224937381942" LOG_EFFECT_SIZE="0.6126135178063749" METHOD="MH" MODIFIED="2008-12-01 17:13:40 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.005069830200953862" P_Q="1.0" P_Z="0.0019482355513180123" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.49276892315516735" TOTALS="YES" TOTAL_1="1015" TOTAL_2="1017" WEIGHT="100.0" Z="3.098011976478143">
<NAME>Grade III - IV toxicity</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="3.042813735475354" CI_START="1.306216255095718" EFFECT_SIZE="1.9936330561330562" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="37" LOG_CI_END="0.4832753680232632" LOG_CI_START="0.11601508399865258" LOG_EFFECT_SIZE="0.2996452260109579" ORDER="13" O_E="0.0" SE="0.21573050880378197" STUDY_ID="STD-Bosset-2006" TOTAL_1="483" TOTAL_2="495" VAR="0.046539652428738656" WEIGHT="38.44156127298051"/>
<DICH_DATA CI_END="18.072803414608675" CI_START="2.5561894691048574" EFFECT_SIZE="6.796875" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="5" LOG_CI_END="1.257025524617466" LOG_CI_START="0.40759304132403434" LOG_EFFECT_SIZE="0.8323092829707501" ORDER="14" O_E="0.0" SE="0.4989608454451675" STUDY_ID="STD-Bujko-2006" TOTAL_1="157" TOTAL_2="155" VAR="0.24896192528735633" WEIGHT="27.95065581657423"/>
<DICH_DATA CI_END="12.239124424712944" CI_START="3.0761783030724668" EFFECT_SIZE="6.1359375" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="10" LOG_CI_END="1.0877503499078296" LOG_CI_START="0.4880115046652325" LOG_EFFECT_SIZE="0.787880927286531" ORDER="15" O_E="0.0" SE="0.35228956645066495" STUDY_ID="STD-Gerard-2006" TOTAL_1="375" TOTAL_2="367" VAR="0.12410793862999746" WEIGHT="33.60778291044526"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5406432370364054" CI_END="1.2954422318684802" CI_START="0.9194226369748807" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0913564554595088" ESTIMABLE="YES" EVENTS_1="583" EVENTS_2="553" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.1124180511002085" LOG_CI_START="-0.03648480775097844" LOG_EFFECT_SIZE="0.03796662167461501" METHOD="MH" MODIFIED="2012-07-15 16:02:53 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6373731873644743" P_Q="1.0" P_Z="0.3175590078151006" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1157" TOTAL_2="1145" WEIGHT="100.00000000000003" Z="0.9994866676303588">
<NAME>Sphincter preservation</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.467726257329184" CI_START="0.880331065856257" EFFECT_SIZE="1.136699177663033" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="249" LOG_CI_END="0.16664506374272045" LOG_CI_START="-0.055353972127714146" LOG_EFFECT_SIZE="0.05564554580750317" ORDER="16" O_E="0.0" SE="0.13040333258324388" STUDY_ID="STD-Bosset-2006" TOTAL_1="473" TOTAL_2="475" VAR="0.017005029148816114" WEIGHT="44.988746770865575"/>
<DICH_DATA CI_END="6.113294996862231" CI_START="0.8242492750056155" EFFECT_SIZE="2.244744744744745" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7862753531623127" LOG_CI_START="-0.08394142618201784" LOG_EFFECT_SIZE="0.3511669634901474" ORDER="17" O_E="0.0" SE="0.5111696438293902" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="124" TOTAL_2="121" VAR="0.26129440477266563" WEIGHT="2.927865795185628"/>
<DICH_DATA CI_END="1.5187194287598018" CI_START="0.6213612939411504" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" LOG_CI_END="0.18147754884885536" LOG_CI_START="-0.20665580346489637" LOG_EFFECT_SIZE="-0.012589127308020516" ORDER="18" O_E="0.0" SE="0.22799145244017788" STUDY_ID="STD-Bujko-2006" TOTAL_1="157" TOTAL_2="155" VAR="0.05198010238578189" WEIGHT="14.717842310686478"/>
<DICH_DATA CI_END="1.387337886766241" CI_START="0.7710339118370488" EFFECT_SIZE="1.0342555573324803" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="185" LOG_CI_END="0.1421822465722409" LOG_CI_START="-0.11292652026315812" LOG_EFFECT_SIZE="0.014627863154541391" ORDER="19" O_E="0.0" SE="0.1498521524478755" STUDY_ID="STD-Gerard-2006" TOTAL_1="357" TOTAL_2="357" VAR="0.02245566759326132" WEIGHT="34.068679856877374"/>
<DICH_DATA CI_END="2.485865958515667" CI_START="0.37618792603241236" EFFECT_SIZE="0.967032967032967" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.39547770715098346" LOG_CI_START="-0.42459514749283345" LOG_EFFECT_SIZE="-0.014558720170924971" MODIFIED="2012-07-15 16:02:53 +0200" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.48171485424387817" STUDY_ID="STD-Latkauskas-2011" TOTAL_1="46" TOTAL_2="37" VAR="0.2320492007992008" WEIGHT="3.2968652663849674"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.437349042073351" CI_END="5.838095317007154" CI_START="2.122309987951338" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="3.5199784092940423" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="40" I2="26.434739262669556" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.7662711813187151" LOG_CI_START="0.3268088179368565" LOG_EFFECT_SIZE="0.5465399996277859" METHOD="MH" MODIFIED="2012-07-15 16:01:04 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.24529188306704897" P_Q="1.0" P_Z="1.087853679339077E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08612736177135516" TOTALS="YES" TOTAL_1="1142" TOTAL_2="1142" WEIGHT="99.99999999999999" Z="4.875041890448337">
<NAME>pCR</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="4.9744264598108305" CI_START="1.8068650885861501" EFFECT_SIZE="2.99801893022232" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="22" LOG_CI_END="0.6967430147906399" LOG_CI_START="0.2569257267336407" LOG_EFFECT_SIZE="0.4768343707621403" ORDER="20" O_E="0.0" SE="0.2583508521353695" STUDY_ID="STD-Bosset-2006" TOTAL_1="473" TOTAL_2="476" VAR="0.06674516279907157" WEIGHT="43.590227969299406"/>
<DICH_DATA CI_END="8.047371309218269" CI_START="0.4806262354698652" EFFECT_SIZE="1.9666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9056540403258698" LOG_CI_START="-0.31819252648090646" LOG_EFFECT_SIZE="0.29373075692248174" ORDER="21" O_E="0.0" SE="0.7188935314805105" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="126" TOTAL_2="121" VAR="0.5168079096045197" WEIGHT="11.0521784221726"/>
<DICH_DATA CI_END="209.89906654370068" CI_START="3.702998579754937" EFFECT_SIZE="27.879310344827587" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="1" LOG_CI_END="2.3220105072064054" LOG_CI_START="0.5685535454805222" LOG_EFFECT_SIZE="1.4452820263434638" ORDER="22" O_E="0.0" SE="1.0299892990697297" STUDY_ID="STD-Bujko-2006" TOTAL_1="138" TOTAL_2="148" VAR="1.0608779561981532" WEIGHT="5.809692502615208"/>
<DICH_DATA CI_END="6.5406354738800045" CI_START="1.8107803497226374" EFFECT_SIZE="3.441461054668602" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" LOG_CI_END="0.815619945479023" LOG_CI_START="0.2578657729596565" LOG_EFFECT_SIZE="0.5367428592193397" ORDER="23" O_E="0.0" SE="0.3276275618655575" STUDY_ID="STD-Gerard-2006" TOTAL_1="359" TOTAL_2="360" VAR="0.10733981929396971" WEIGHT="34.44381708346279"/>
<DICH_DATA CI_END="47.02864897434985" CI_START="0.6200475802718535" EFFECT_SIZE="5.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6723625026369453" LOG_CI_START="-0.20757498299100816" LOG_EFFECT_SIZE="0.7323937598229685" MODIFIED="2012-07-15 16:01:04 +0200" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="1.1042845848984963" STUDY_ID="STD-Latkauskas-2011" TOTAL_1="46" TOTAL_2="37" VAR="1.2194444444444443" WEIGHT="5.104084022449982"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.398042931815211" CI_END="1.843884311485057" CI_START="0.6200806647981789" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0692787333883464" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.26573366917976377" LOG_CI_START="-0.20755181050496882" LOG_EFFECT_SIZE="0.029090929337397476" METHOD="MH" MODIFIED="2012-07-15 16:03:39 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7059937572141157" P_Q="1.0" P_Z="0.8096000738406952" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="563" WEIGHT="99.99999999999999" Z="0.24094199473890152">
<NAME>Anastomotic leak</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="100.71181947500082" CI_START="0.2298858946951921" EFFECT_SIZE="4.811676082862523" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0030804420685087" LOG_CI_START="-0.6384876752899835" LOG_EFFECT_SIZE="0.6822963833892625" ORDER="24" O_E="0.0" SE="1.5516701881094457" STUDY_ID="STD-Bosset-2006" TOTAL_1="267" TOTAL_2="255" VAR="2.4076803726676026" WEIGHT="3.210130831558219"/>
<DICH_DATA CI_END="2.3615869992399094" CI_START="0.3178471147983168" EFFECT_SIZE="0.8663853727144867" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.37320394931727463" LOG_CI_START="-0.4977817264479563" LOG_EFFECT_SIZE="-0.06228888856534082" ORDER="25" O_E="0.0" SE="0.5116212973931259" STUDY_ID="STD-Bujko-2006" TOTAL_1="87" TOTAL_2="86" VAR="0.2617563519462254" WEIGHT="29.527340747878686"/>
<DICH_DATA CI_END="2.1231103056190856" CI_START="0.45490547711236695" EFFECT_SIZE="0.9827586206896551" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32697255840397405" LOG_CI_START="-0.3420788341848659" LOG_EFFECT_SIZE="-0.007553137890445899" ORDER="26" O_E="0.0" SE="0.39300409986449086" STUDY_ID="STD-Gerard-2006" TOTAL_1="188" TOTAL_2="185" VAR="0.15445222251029872" WEIGHT="50.04116400022988"/>
<DICH_DATA CI_END="5.504649244994623" CI_START="0.39833192219952995" EFFECT_SIZE="1.4807692307692308" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7407296510431967" LOG_CI_START="-0.39975488796783126" LOG_EFFECT_SIZE="0.17048738153768273" MODIFIED="2012-07-15 16:03:39 +0200" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.6699262637045952" STUDY_ID="STD-Latkauskas-2011" TOTAL_1="46" TOTAL_2="37" VAR="0.44880119880119873" WEIGHT="17.22136442033321"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.243361206570629" CI_END="0.7195228413171644" CI_START="0.38541075583822276" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5266040657979332" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="122" I2="52.867552333204586" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.1429554147912414" LOG_CI_START="-0.41407616945221326" LOG_EFFECT_SIZE="-0.27851579212172733" METHOD="MH" MODIFIED="2008-06-22 13:11:28 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.11983013224667949" P_Q="1.0" P_Z="5.6529749555010704E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="740" WEIGHT="100.0" Z="4.026847169017638">
<NAME>Local Recurrence at 5y</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="0.799738324345597" CI_START="0.26793481855621987" EFFECT_SIZE="0.4629014396456257" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="43" LOG_CI_END="-0.0970520916118377" LOG_CI_START="-0.5719708454651035" LOG_EFFECT_SIZE="-0.3345114685384706" ORDER="27" O_E="0.0" SE="0.2789696268991545" STUDY_ID="STD-Bosset-2006" TOTAL_1="253" TOTAL_2="252" VAR="0.07782405273225346" WEIGHT="35.23108413920462"/>
<DICH_DATA CI_END="2.04440163211985" CI_START="0.5050133592115059" EFFECT_SIZE="1.0160955347871237" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.3105662189963483" LOG_CI_START="-0.29669713325737734" LOG_EFFECT_SIZE="0.006934542869485497" ORDER="28" O_E="0.0" SE="0.35670949911591227" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="126" TOTAL_2="121" VAR="0.127241666759525" WEIGHT="13.96677959588946"/>
<DICH_DATA CI_END="0.6933185358273091" CI_START="0.27444460067348964" EFFECT_SIZE="0.436208125445474" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="61" LOG_CI_END="-0.15906718881044696" LOG_CI_START="-0.5615453089551505" LOG_EFFECT_SIZE="-0.3603062488827987" ORDER="29" O_E="0.0" SE="0.23641764007182497" STUDY_ID="STD-Gerard-2006" TOTAL_1="375" TOTAL_2="367" VAR="0.055893300537130985" WEIGHT="50.802136264905926"/>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.7307165601001724" CI_END="1.1665804124680559" CI_START="0.8375315489010395" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.9884573333088204" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.06691468011006589" LOG_CI_START="-0.0769988245829765" LOG_EFFECT_SIZE="-0.005042072236455316" MODIFIED="2008-06-24 16:01:02 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.8659564404906119" P_Q="1.0" P_Z="0.8907649146373032" Q="0.0" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="0.13733638148803357">
<NAME>HR_DFS</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.535281945848084" CI_START="0.4599191407242372" EFFECT_SIZE="0.840300870702801" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.18618814286332397" LOG_CI_START="-0.33731851576204425" LOG_EFFECT_SIZE="-0.07556518644936017" MODIFIED="2008-06-24 16:00:11 +0200" MODIFIED_BY="[Empty name]" ORDER="71" O_E="-1.84" SE="0.30751040267629504" STUDY_ID="STD-Bosset-2006" TOTAL_1="0" TOTAL_2="0" VAR="10.575" WEIGHT="7.557161080084467"/>
<IPD_DATA CI_END="1.804087236907384" CI_START="0.703772271808353" EFFECT_SIZE="1.1267948230528768" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.25625753408811613" LOG_CI_START="-0.15256784809737436" LOG_EFFECT_SIZE="0.05184484299537088" MODIFIED="2008-06-24 15:59:58 +0200" MODIFIED_BY="[Empty name]" ORDER="72" O_E="2.07" SE="0.24014605321403706" STUDY_ID="STD-Boulis_x002d_Wassif-1984" TOTAL_1="0" TOTAL_2="0" VAR="17.34" WEIGHT="12.391600295854815"/>
<IPD_DATA CI_END="1.455789869935428" CI_START="0.7429628177961558" EFFECT_SIZE="1.039998915329398" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.16309869303102612" LOG_CI_START="-0.12903292033097064" LOG_EFFECT_SIZE="0.017032886350027695" MODIFIED="2008-06-24 15:59:37 +0200" MODIFIED_BY="[Empty name]" ORDER="73" O_E="1.3319" SE="0.17159955576364505" STUDY_ID="STD-Bujko-2006" TOTAL_1="0" TOTAL_2="0" VAR="33.96" WEIGHT="24.268670475618773"/>
<IPD_DATA CI_END="1.1984356712323339" CI_START="0.7690025493472206" EFFECT_SIZE="0.9600000450032866" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.07861472724858828" LOG_CI_START="-0.11407222045137112" LOG_EFFECT_SIZE="-0.01772874660139139" MODIFIED="2008-06-24 16:00:49 +0200" MODIFIED_BY="[Empty name]" ORDER="74" O_E="-3.1865" SE="0.11318526689473016" STUDY_ID="STD-Gerard-2006" TOTAL_1="0" TOTAL_2="0" VAR="78.0585" WEIGHT="55.782568148441925"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="0.12189141299628725" CI_END="0.9525681659625933" CI_START="0.5226809683843427" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.7056126780588807" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.021103936343004493" LOG_CI_START="-0.2817633129424951" LOG_EFFECT_SIZE="-0.15143362464274976" MODIFIED="2008-06-30 17:15:55 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.9408743284113161" P_Q="1.0" P_Z="0.0227661873563425" Q="0.0" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.277335687825219">
<NAME>HR_LR</NAME>
<GROUP_LABEL_1>CRT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.146822412115082" CI_START="0.41038553647521325" EFFECT_SIZE="0.6860315815162201" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.05949617168532744" LOG_CI_START="-0.38680795379217825" LOG_EFFECT_SIZE="-0.16365589105342535" MODIFIED="2008-06-30 17:14:56 +0200" MODIFIED_BY="[Empty name]" ORDER="89" O_E="-5.4829" SE="0.26216125254653816" STUDY_ID="STD-Bosset-2006" TOTAL_1="0" TOTAL_2="0" VAR="14.55" WEIGHT="34.11024995428523"/>
<IPD_DATA CI_END="1.2999915003106406" CI_START="0.3250065180910023" EFFECT_SIZE="0.6500043931112" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.11394051278356429" LOG_CI_START="-0.4881079290439911" LOG_EFFECT_SIZE="-0.18708370813021344" MODIFIED="2008-06-30 17:15:27 +0200" MODIFIED_BY="[Empty name]" ORDER="90" O_E="-3.4444" SE="0.3536462349173569" STUDY_ID="STD-Bujko-2006" TOTAL_1="0" TOTAL_2="0" VAR="7.9958" WEIGHT="18.744930349448374"/>
<IPD_DATA CI_END="1.1518533900126195" CI_START="0.48058569897550507" EFFECT_SIZE="0.7440189960992393" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.06139720481594559" LOG_CI_START="-0.31822915685386766" LOG_EFFECT_SIZE="-0.12841597601896101" MODIFIED="2008-06-30 17:15:55 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="-5.9463" SE="0.22299440402564558" STUDY_ID="STD-Gerard-2006" TOTAL_1="0" TOTAL_2="0" VAR="20.11" WEIGHT="47.14481969626639"/>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-07-15 16:03:40 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-06-22 13:15:58 +0200" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.1 Overall Survival at 5y.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs8AAACwCAMAAADHR3O4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAeAElEQVR42u1df3QcV3W+0mpndnblld5awnZiO5athp6QhiI7kVaS
GyI70NSloS3QnvYkdfpHoKcckj/cAGlpCIGCAylNS4AE2hBoaElDmtA4gYOtQ5BWthdH4QRKcZC8
in/JWNKOZGu1Wo2k7ZufOzM7Mzurnf1h6X6JvLMzb+5798337tx5881sHQEEYtWgHrsAgXxGIJDP
CMSa5/NA0M82xqGvr8/Pcq3iJ4UXhqkZhuEGPbRYjFchhgkKakP0H7rG3daqfm3hTNtrCC1Blgm1
FHCF9rN2PMvpSs3zuWVv3a+nb7qZLvULh6Oz0N8P0p8X6F+Yie711KJbjO9dupCCRsGxceFMSv1y
Q7TybXQJ4VJ29sLy5daC/azgga5yulLzfJ7vmY5w/WlpeTcse2yd89yiO2zs+WHEP9XTDEKQFWeY
4lygWYnaXFwtNAkCCCGG5QYYGtKkoHaAZcM1doCae5P+SKjnouqDEAqIHrVyNGq36vs5HmT8wbTm
SpZlwmuQz38Gl7XltOfNHQBfVbwKwNtEdxahoSu4JJ6Toy+KA+vWzgtvRm/WTk3gh6aXF2aj31qg
IU1c0zQcPLSrqbYO0CL1A96AD6o+NHQGk/TjD6OzTZ2z+n6+eWphrouoroT3HAqVwZWa5/MIRLQ8
bN/xS57a7ut74NgrVfEqK3oVoR8sjI7R753QIX4sw1XffzatNu6G+AzM1YfD8JR2soLRMGRq6wAp
rjyl+sDCyE/oxyiEhc+l9f2cPnEgDEvqbjdCxyj1Z83xOQZJNQt7cNBj2/0PDkB7lfxKiv/XQS9E
IjIpxI+Zwe5vXaXc4er/aWzpMpC/Xz4FPTru3JSjRG2gTnZF86FXbCPA8FC0Y3da38+HH/hKI00Z
tYgdEcfzmuOzH9api7uDnR/31vjuxq5tVfEqA/8rJpUN4nAVuTAkf3AXfnqke05lPBclkILTbG63
/WKxvbV1gBqoH9SbedUHxSP+/B3xniZ9P++DMyf1xEuK43nN8flXsebkj/uC0vL00X8WvLXOH00L
1fDqQuw7yanIYJCenXdsk64MhtvoR/B9vsXcQZ4eYlvr4a3DdLFdPkt9B3YMU97UFILtkankrbEL
qg/z0C56xL3vb07nLk7kfs7syJ1wGRjeQS8jvIaPq3E+P/Kjbz48duTiwTZIADR2TgkgLXkAyU6o
y0OLRXhFfvLwI77L8zD7tjfYTZD4yUNvXqAfc++Nsecb59TGresc407Nf/cqSCRGHhXoqvH70t++
eKm2DtDcaeELX2gIPQSLE5IPi5Pzj70OiaHPpD9/ITSn62eu96566krTyBcXJVdOjUzMeJ/9oB4J
sYqA97sRyGcEAvmMQCCfEQjkMwL5jECsIj4nG1lmTyguaW11cNCqxrN7GDYkuCjpBg465IFgwfIt
QesWO1kNFbbK2VgVIMn0sUkQ+gJ525UlYz9SowIM9OkFwtoecpWWrdRWxhsZ5oBA65PKNjOPAzw6
oPhxG7NHUogb9uTE29Ac4+3tolK9SIZYJqx5QZhmgMa0eowVnXtJDdTdT7lqdvryL2751GLXFsPd
BYebDd/e/fTDs7f87quFS7pBG/QnEtYW3txssT6REPdQv3XlihjaUaLVLTZWZ9P/eiNs/cRc68Y3
6tQdTSWN/dgGMJt+fhPI26QimkWpjWDZSq3Mf9yU9MN0ZuHaI2O04J2xI0vj73lC2jLecfbc/Ts/
LZi6/3fuy8DjN016y2fqxUl/CV481vmzlg7Ri/hJWjCbuutVgVEix9d95z9xy0OLJZJIF5/vg0Xg
+uf9qkCV/slaVq6vVY1Dsv62r69RGgYCXEf3eEItDdB0GydAPBholgZqkIbMMMs0gVqgr+9JNujc
wQPSre1gXzrMsOEk3SPNBSKSZtaoDdZBapNUROBYhotYFEn3iaE41EcOMGxWtPokFyCsuEsLjQqW
TRLrl63Kul3T5gX63yBk6L8kSX08IBql4fC2Zqkf0iE2LfWjHizdh3WMfYI/CMkA25oUtcFJVRut
Vpgcpf9sBGnVU/4s/KZibGMPF0n2z5nNDWVaWlPHplVbko6a1hEq8R7zEOXCkLMXDCeeGFqUflH0
0DIE4EaoFxvAL37L+p+C9YoXep27N3yuhw7qMa0StKcHZC0rQ9d9C8R6Nf3txDkpuMM7uAG9teyx
6Jfhxq4XF6VvU2egadeh0M7mXIF7Ql0Nju3ZfV2XAONdRzfuCoV2baMrNjR2z0maWaM2OAe5TVKR
cDKTis5ZWOWOdo6D0Hnd8nDjD/eIVu9t7E5nxF1u7Pr1ui4LXXnzrhCnWJV1u6btS3TwZ+jfEvjb
dv2wUVIuwNboMV7aGgj23KPvR3mo0tIDjs77g12krTswsW1PcGZXm6qNlrFflD1kRbUxE5qiR2l/
MnNK3hKAk1bG1mVTf1I/A4otWUdNV798vjTCHKSeH3T2gouS7dHApNIvih5aIYjsxTLM3U292E+z
tj9VvNDr3L3h86UhiD4QMkRAWct6gY6oD4uxKqe/TUtR8BXzHmOj8D3av2H5qKbX07LhUdANurER
YJ0z6J2wHh6Bf6I1jUg6ycMTyiMkem2wHpmcJji9Jfzh/AdORKsBanM9PD0PI9dTZ+jpUrV6BK5e
srKahtFTsEteNOh2ZcSi8cVBPraYjNZNZCAwIit5O2FUHsn8RE6znDvO3UK3X98qYxulnGVobn4o
ATfCaJq6pGijVdZy7aK+sm62sfMa4EI7t7NtrBQpesDqlAQTwegvAn7Vlqajvj5SGmHC0dbucAEv
2LmdQ4dB6RdFDy2DgRfER1WysXC080HYGeLavrOdkbwYgYgXfNblz76LH0ts2SxnMMrfzfChr7XB
2fPLZ//xrCiD8W2l38eW2+BD0h5fu/jRMd0edPXBtsGl+mvu98nfaO9fc//BtjNL+gJnlhzz5yfv
FSbef/bfvrD1mWfgFbrj/dC2NSHu//Uv97x+77r5vLRMa1MCmn/7rx7fIJc2WT1/7/GjT5w5LVmV
269YbRrt3nRPON9qw1bJF3H58EPPhzZcY7Qa2PwP0fOfDnQfuDq+UHfN4WfgtFj03NYPqZ63mZoh
tuO5qc39z6mZZ38iYco86deDoc6tFz8F58Rmvrl0s9hdapnBZAO8WbckJHznnkkszS998+C0Lzwn
Dp9zW189aHX5Mt8GvwTVFvnl2dHntibUI7fy/PnpDXeffHqDsxcTnXDxS6D0i8whpUwq+UI4Ub8k
LM09+cxzSy8unf887xt7RPTivI0XJczXRabPv6YEopiUd9AMUdKy+nt/o5dRTnoG/W1k5vwwHW6D
oIjuJUmrD5JaQuqTVw2oBeLJQg2KML2be5lIHTzb37+g33CXXhtsgNamObjjpI1Vtufm3oBs1ZAt
J8d/2tFjZ1XuHKNuV40zCzTw+MUHpqiPalPr5O6ywaaYENuUF9MMEDJDsXSc1itZjOnN+WeFVFY5
WuIVaHuDv3tiSW7LWx0PsGTLqKMuAROx+2ITBbyYjw2lBbVfTF4szNb5dF7M+bs3SWdKnc7dIz4H
+iKR79Hj0y49ODHeIp3LJS3rS3CTnKOZ9LeBvnTkf+ge+6FlmzxEd9B2pWG4IXfcJZWrD1rlAnvb
oVC3jg12DYyJuuDxPu3cIWpmg+972VIAHpDbRIcebce1O2ysJtqjgwmx7Hhf0Gi1/rPwF5ZWt9PW
y7rjTJ5VH/TCRfg/6KZ/1MdW6XoTHpbFzArawURuf6+UbvTrnm42kWJ9d/BQbx+1uF3o07TRchmO
bY30chC8u0XuwjQPQ+PS0eOYv0tG+oI2jiu2FB21B/D3FPSiJ/Ri75fVflH00KoX45GeKdrk1p/L
XixCrFXyQq9z94bPl4+nmE/GfwTPDm4BPvaXYqsXj80+Kh7cQRjaJLHiRGrfiZxo9cfx3/fvjU9D
NDYrz7r45ob6gT/6CAHl0aixE/tSJ6aBH7r8klzd7PEp5/wZIhlYiMBYR+qa3LN9ocGrYeb63Vcd
sxjDSpseH9xM2/H2pJ3VMDARsey241r7g7HNMBO/FDr6mIXVjtTOE5ekvgi1b8tLkSZpj/hhEx1G
LIwd2TdzfFpcGz2WrgftoTBxX9MgyL8WNlwgCruOJvcevall7MTOUHwGptiUTysTqp9J3ZGE0NOX
3nGEZtUDPj+w26QBP/Hf39+YosfNJjzItoJDM3/kDZ8bLLwwPAjXuotN7h16oUXpF4VDcplQ3ba5
1zho9M/cekL0ot4P3IwU4TYdXt7w4JGzpbbOjf45CVd1vz7p2iQTPDXyseMpK75Cbb5Cwiuw3Kl1
77b03A7j29OelKkuWlJpT8p4ADd8ZrP1waR7kwPvWgJ/cMLy3LewqvmcJtmsted2aHx5tydlqovQ
JOdJmQrxGYFAIBAUf1zZ6howPiPKisoSDPWiiNUE5DMC+YxAIJ8RiLJfD+qWecv0nSfi/4bv+n/y
Ia7mZTtyCV62yqvG+WIvEcwGrGosXMrCKhC3Vm0abSyjawMp6Ka2Oa97DDtb1a8rqvkAhDf54VHn
X7l8BjuSWnDcoVtyR4PP8ZuoH+raYuhsMmBFzMKlbNxyZ9Wm0cYy+jY49hDoeyG/3SR/q6H+XFGi
j0KEd9ErfC2QTpRqhivAZ+P4Nx2mPFrr1ho+6KFU47d3vUec6G4+sRC3owTcWrV2xXKty5ODYVdi
2jXPsGEFAUtyu2hbNWAhw3veejV4IIdosI+HNuv0gcc4+rUyJBc9vOlo3oklpJjCYHHWdmGVuB1k
fG4EuB6fanKWW0lcDxJzwlNgjyqwvL+o1Z7ymQd3h5h2okxZYh9i8lNVfsVz6/JYKWxAzerd5Rtu
E5NiMk6tpeI5ynWo1gcE9ymYW1dK7PxVmD9rHZLXK7xuo12nyUe3+GNmHisuM2NSlFGPQQwd6Xpc
ldgepxhUcueXAeEK8blgNCOWUxlafCBuLif5sl1jl8fsyqyW98Sem/0gxXGdX+0THPXuLsL118VE
nyNLG/i8MtZGpL3poKgJOvPVHCTeesq79bJ8nV+T+YYSanPpQy7IWOcSSpGC+YbDVjenBlcGeDkb
cl1NUVbdWNKn+EoS7YaZDu3Iu2hQr/7k5I84HxxvOv8KA+qfaz76uj5Z1GQm0VfZR5LwfncNErqi
u63ifANRCyAr2rRG8gmMzwjkMwKBfEYgqg2c30CUD+pPf4YrVmOD+RLZlWjXSlYH5ZjidKVs5nMS
S1JQhKL3gkBBqybjTmV0tkvWP1srnJ33Nc13V+wY1e78hlvtsKWsrgjhsXs6W1Rn1xqDFtiF1Tzx
spOP1tJhi4bxyvrS9M82CmfnfY132Ct2jGqXz7n72JqQmRgXC0lnvKazQYNMClbq7nApVgsoLPKk
gxaGyco9z6udFIoeVvuuZGqv/HTOeebLW0MqyGetRp7khQ3lqYsCfnjcWlIsR1zlTEXq2Xin563M
nueoVoT+uVivSElcKz+fSV7+XLlTQoN1Rqg1gxhaRHiwP1zl1CPyjg+/8aZIWUwz7JUNvAvZp3WZ
4vTPAC6GgP1TYfbqjAofo9rLn0HROOvjML+CYVlpGLQ5Kxgp1oeYqBrYgjUTM4OI19Qhjg1wnxav
+tmsBjcpaXGhpOLhuRJt4l0/w6U+csl7U8XKveLX4lRsvenUa7xQN0dovhbpzDt88+KipogypeiL
CyToRTeyFugcDoffS/8qN/1set6Kzz35TvSpoGnRKDUuu8RW1fuCo766YD5cXP7sxitjGcMbMorW
Pxu8y7NoUUUh7XRlj1GtAO8P1hxQ/+xRvoGoEUJXdLe1cD2IqCJQ/4zxGYFAPiPwehCBcIVL2lIF
p+swPiNW7fWgG7VlhQXQvF4v6aBUBlJMK1Zm1Vr/bDTh/v3PFvtA7r2MefrnvOltkxUe9c/58xsO
76/LJ0QlxLV8rlnOSgso5v3PK7Dq+IbRlbz/OW8fg37OQv/M5zmg31d952LlD1Et87nw0OadDi54
PfiN6kvifMpw3Qp3mk6eONehW0u88dX1litD/+wzDz9SLT47DG3iTgbsEQi4IF7eSZQH4r1VG0Vm
MaOsMAucftKCOGni3aufKqd/vlTBEWTD5/wk0V77Xg1xrc3BMJ5Ei2yFraTBaJXYPaCSe17QYLMo
/TNvX0MJcR31z8b82aRh4V2Oy7IOfBe/7rICEX1hqwXez29uWDH6Z/WdlitlbVHngjWqfzZEH2KV
vlZ0lNfSi52LTv1L5FhuQsn6+RRiu3XN658t03rrZ1Wq0Vd8keu9rI132UMrr8jZiJ2wWpkEsdq6
JulsuD/I6yaI7D54sJi7LfP8s2nS2910TEWsmn7Xy/hrgc75c94+hl8INP/CmCkx0n4oRovv+Q+B
V+oQFUCF9aJ4v7vmgPrn8uQbiGoRuqK7rZ3rQURVgPpnjM8IBPIZgXxGIJDPCATyGYFAPiOQzwgE
8hmBQD4jEMhnBAL5jEA+IxDIZwQC+YxAIJ8RCOQzoirIhpLIZ8QqQfKV6fTVFSS0j8M+R5QNwr9c
hPTl+WO+KsTnPgnqt5agboP0EQmA0Miw2STE5ZJNbDM9naSV8hzDHBDEsoHKPfgToi0TsgzbSNvU
uEeuX+9ECQciy+zJxiEZYpmwAK0hhg22FqpbDEeNLJMVoJmhPdMYcbAflNuolBe0VosfwgGGaYxL
raD1hgSIh+gKIbdzo7zzAF0diqsue+K2x2gNXhA/DnJCFeJzItEG/Qn1W9dmbbENxMXk+V9myI1P
Ptv9wbrvbrz9K4kE1IXnFoVQndzyS/5zn1g3JdCywczFg5UZ/Ou6aMtI75R/14GFJ3bf/zxMZxKJ
xMzG46V3X/2e6UfPfS7zWOfPWjqmM/VCE7uz59W8uj/KqXW/kJ3O0NWf2z3JdtOlsUcWBf/lAi3P
lV+4Nn4ykZD7uh9IXfL5Ux8X+zXcOf3SryYW/73rZ2/pmFKdGv9qp7zzfy6mxo9/RqAuX94QX0jI
h6mWMPDVCXmB2/3tJ6uWPx9g2TAwNFSAwLEMp0aZ7SM+mIfdo/B7sASfFNcsTyzB+oC8Nd0biHD9
KXHxUPeOyrT93dK/CzA6CruBg45RukzHXefgdOm2WZjsoOYE4Ebox+zCxGl4Or/uL2l1j4BIZ9o3
p8TyS5uWoYEr1PJc+Q3g121dgJEO4OSlyd2wTPubm5R8k/Dny8pCesHPgsjy5OVYLaaN5J0T6+kH
/Zs6ej2pFp+bhoOHdjXR3uuHcDKTis6pMQVGoA5oan8EPgXvZ4NJqB+vTy6cUre+oRq4Tj605Uf8
jHT9DJEIbdOd4kdWHHcZzl+6bcnTO6nBJEhWb9t39LRN3VvkuiUckVtRL9QL3KhDy8+CofwyzN0d
mtJmBMSVd8qjqiVNqf55GGjJ8fn2czlD22G/GNR7AhO1R+fwzCSIPsl/p5qqxOcMjIYVRqa3hD8M
yxqfI7Rr21+gi38beyzYtQUC27jtzH+JqSJAD0RyVFiqTIfNrpdrljAiMwGS8zEvTrsN0M7BU/Q0
9QIn9cDTd0Svsan7G1rdAL3yEhcKtLLbmcdtW652llI+GwtHOx9Ut0pWnxL/OT10w77YaYgOPXBD
3aK6+Z5cXj4wB1Hq8q5YAmoQU4Zv01XiM40ONymMbL7hoefkLpdoSvv39tRfx+jhyPhHYZFmq6fS
Yx9JfUDcGgNtUkYOkxVDTP4YVNrY3j0f8cDqmeOpCLXMxz/YOij2UeT2XIC0rVtbml44NZ/4QOoj
BatRyqcyE7fDVw1WpT4k3a8/2LMFbuk+9HrW4k0pA3t7X7uLZqdZNlKDdL60HZR0g/6t31ZXrfwZ
kknYKy3MwR0ndTxPQuSezFzWr34HGGYjPX4pkvjhWm13qKtkt9WJ7d0DPvFDCgrf8MJqJJVJUwr5
Zxdm63y2XaWvW3J6j7q0g4mM+AuPa628OiDkiuhKqTZGzJ8XxSx+UryiMV9V3pp9XXwpUiv4oBbB
S9dWU2L+3NI8U638OQA7hmGIRo4kzc2uzV3aif0ZZIQf97LAsS2cdMHyHhba5cturn0+me4LiYvr
KvvSJdqEYXiJDqgd7fR6lTbrD7ywGrxbIL0M9XQ80jMFHNP6c1qRY92MOFcZg+EdUk9lTkJM2O9c
R6680T4DO3bAF8XNfhhIU7L6IN1Clw0TcvTL+jubJsXFJRitST4DF2mR045WUqlbKvl8TpxI7Tsx
A48PboZo7O25dtDcGX7gC372tSS84rvU1EFTtpb6CdgZki6tJ55b2th0QsqRFullfwUxeWR2X5yH
w/HUbMeieNpY74XVH5wJpYd5CNVtm3uNg0b/zK0nZpzrlrLFsfi+1BG61AKbgAvuLFiNUl6yP6ZZ
7Uil4tK+M/E9zcdn4JV406X4jJbeaFc6I78lTTovQqQ2+QyT828RP96enqzY2dr1PEpyU8DdOSO8
cL5W+7f20Qf27+NsvTy/0l2rhmTLFGy67Ifa4zMMvCvt7lQdSCIvVwoGsrY3g0KcU5jz12cXanGA
Hq0/U8Hwhu9/RpSXz/j+ZwQC+YxAIJ8RyGcEAvmMQCCfEYhioLs1rfw+kv737sxL1ijf74SV58fz
DL/0V4Wf5ENUhM+k5n7BTvmRSOOHV1aVAcyTtfpTqmsm3+B58fegpR+F5vm81ZDbQMtYlvQKxLBI
vLdquwZx5cdnY/wi5oho/r1dLWoSD2OnbYZQBtvqT8bzyOdVzWfHuEXJq+MtKXeUU34unKgJAvF+
eKjGEauez8af0OXtNkg0Lw+fZa4RwzePrKqmkMtrhs9SFmEZf4lFKL/SohyPF4Jr43rQNkJLc1ta
Dg0O8dozxpWhDnVekhCMzWshPqu5g3ilB4S3SilM6YVUsgzkUKwaP7yyWuZMCVEVoP4ZUVag/hmB
QD4jEMhnBPIZgUA+I2oQ/Io3ui73XSh/HTzyGbE6oZ9/lu+UuNc954+T/BvS2ly2UkAcStZFlGFG
8hXJ8m1KYr2TpisiFqPWqOWW6tY10LI1uruiarV4F/HK5HPJIGDJDb1+ieSdO3JFFE2ylVbP6juf
E+WTAkV07dMT2qI1OSorTTHorxBXJp+l0MZLh1ORZmiLYsjitSAqhrjcQx7iN14rr3KM5LRxkhXi
MAh4iygrVWbaUBTFlABuiMx667YnG0ygvU1uy1ZHAT7nK6ANT4nwYFJA52IhUUXFZvFSTvKpUzmR
whxSxlHueRJwjNyWRYghARFt6daYW6Oposla4DVxzh7dZpll2uraig2feXd+E96pQ4jlGZoYP0le
CDaaJ1bVEVsXtTyYFDh41mHedi9ZwIKC/ys039CumvjCFPdQ+2a6ilzBsy7Es0IWhEfB/xWfP5PC
JCgin7Vgg3W+UYA2hp2sy/LFZ9emvcwXpDzhkSWrYH7DYdqOt05dc2JSAvpFK+aRIlIo3mrQ2Oy1
snyQOOUkqxlkxRtdlytl6wqsNNikjTkFtJZkaipkaclORKybRQNX6mLCm1hkWGGQYOs5rhq2nU5z
suuesuLF42rOn3nLF67kjqbj4TOUsyno2NVutee87cncbGFF+udCeYE3b30h3pYrIT1fvTBM0uc/
ye/cV6abADZMJB4cCsuMlVhZKPp+N09RCTq7P2fyZRkma5HZK04H7OnsSUbDE9eGi74/SDwo4d2c
RfH1EQ+buGZS6WLSlnJwgQfHu3Cl8BmBcduStys78XltHvV1iGoHdy/NI58RVbzc8Nw88hlROt/4
mjGvm6/jLYN73myOy3aadULmWVydxM2qVvPMpm4GsrDeObcP3qp2daXFGwW32kre+Wyvm9C3LcaT
AjwlrltpZdh5/tl2YqRIVvD5kgxHRXMBeTOYblfyxM0+Ol0gYq3A9v3P+tdA61/xzCsB1fJt0Pnv
gVaN6DeqdnkXY7jQfH0Vcj5EDcP2/c86EbR8U5kndneO8kXSJlvEoJLWXhpNrLIkYn2qMf5GhLt9
lPwJ6b22+VxgosQoTTa9DdoldSyVzLYKI+WJKt6Y6pNC++Cb6ZDP+qDnng68/aWoi7eQOsZPa8W9
K7kVCjWQzyYOuaSD8cE83pZ5RciboZiRhKRFOOcbbucFCJ8nr+cd42/+dAlPnNhe4HqQ4PUgogCf
Ta9b5o36Z8j/ZhRJG/Ruhp10CmrQngHnrWYhc1LlvHc/u9A7G/dBdq8lXHnvf16J3hmxVnDl3e9G
vTNiNcVnBGI1xWcEAvmMQD4jEMhnBAL5jEAgnxEI5DMC+YxAIJ8RCOQzAoF8RiCQzwjkMwKBfEYg
yo//B+KJHpBHPkUgAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-06-22 13:16:07 +0200" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.3 Disease free survival at 5 y.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAswAAACgCAMAAAAvpsogAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-07-15 15:58:38 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.4 Mortality 30 d.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAroAAADQCAMAAADf0zI+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-07-15 15:59:50 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.5 Postop morbidity.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAADACAMAAAAp+7sVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-12-01 17:13:41 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.06" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.6 Grade III - IV toxicity.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAACwCAMAAAAi2bbUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-07-15 16:02:54 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.07" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.7 Sphincter preservation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAroAAADQCAMAAADf0zI+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2012-07-15 16:01:05 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.08" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.8 pCR.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAroAAADQCAMAAADf0zI+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2012-07-15 16:03:40 +0200" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.09" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.9 Anastomotic leak.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAADACAMAAAAp+7sVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2008-06-22 13:11:29 +0200" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.10" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.10 Local Recurrence at 5y.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAACwCAMAAAAbvgePAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2008-06-24 14:51:03 +0200" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.2 HR_OS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjEAAADACAMAAADC4MJTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2008-06-24 16:02:08 +0200" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-001.11" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.11 HR_DFS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjEAAADACAMAAADC4MJTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2008-06-30 17:16:28 +0200" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-001.12" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 radiotherapy vs radiochemotherapy, outcome: 1.12 HR_LR.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAi4AAACwCAMAAAAfZxX3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>